Molecular mechanisms regulating macrophage response to hypoxia by Michal A. Rahat
REVIEW ARTICLE
published: 16 September 2011
doi: 10.3389/ﬁmmu.2011.00045
Molecular mechanisms regulating macrophage response
to hypoxia
Michal A. Rahat1*, Haim Bitterman2 and Nitza Lahat1
1 Immunology Research Unit, Carmel Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
2 Ischemia-shock Research Laboratory, Carmel Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Edited by:
Amiram Ariel, University of Haifa,
Israel
Reviewed by:
Francesco Saverio Di Giovine,
University of Shefﬁeld, UK
Seth Lucian Masters, Trinity College
Dublin, Ireland
*Correspondence:
Michal A. Rahat, Immunology
Research Unit, Carmel Medical
Center, 7 Michal Street, Haifa 34362,
Israel.
e-mail: rahat_miki@clalit.org.il
Monocytes and Macrophages (Mo/Mφ) exhibit great plasticity, as they can shift between
different modes of activation and, driven by their immediate microenvironment, perform
divergent functions. These include, among others, patrolling their surroundings and main-
taining homeostasis (resident Mo/Mφ), combating invading pathogens and tumor cells
(classically activated or M1 Mo/Mφ), orchestrating wound healing (alternatively activated
or M2 Mo/Mφ), and restoring homeostasis after an inﬂammatory response (resolution Mφ).
Hypoxia is an important factor in the Mφ microenvironment, is prevalent in many physio-
logical and pathological conditions, and is interdependent with the inﬂammatory response.
Although Mo/Mφ have been studied in hypoxia, the mechanisms by which hypoxia inﬂu-
ences the different modes of their activation, and how it regulates the shift between them,
remain unclear. Here we review the current knowledge about the molecular mechanisms
that mediate this hypoxic regulation of Mφ activation. Much is known about the hypoxic
transcriptional regulatory network, which includes the master regulators hypoxia-induced
factor-1 and NF-κB, as well as other transcription factors (e.g., AP-1, Erg-1), but we also
highlight the role of post-transcriptional and post-translational mechanisms. These mech-
anisms mediate hypoxic induction of Mφ pro-angiogenic mediators, suppress M1 Mφ
by post-transcriptionally inhibiting pro-inﬂammatory mediators, and help shift the classi-
cally activated Mφ into an activation state which approximate the alternatively activated or
resolution Mφ.
Keywords: low oxygen tension, inflammation, post-transcriptional regulation, post-translational regulation, M1
macrophages, M2 macrophages
INTRODUCTION
Many physiological and pathological processes (e.g., inﬂamma-
tion, wound healing, acute myocardial infarction, retinopathies,
atherosclerosis, solid tumors, and more) are characterized by
both low oxygen tensions (hypoxia) and presence of mono-
cytes/macrophages (Mo/Mφ). Mo/Mφ are essential regulators
of inﬂammation and central participants in hypoxia-driven
processes, and the mediators they express and secrete recruit
other cells and orchestrate their activity. The role of Mo/Mφ and
the effects hypoxia exerts on them were studied mostly in solid
tumors, but the same molecular mechanisms apply in other clini-
cal scenarios. We review here the different molecular mechanisms
exerted by hypoxia, which regulate Mo/Mφ functions. We elab-
orate on the hypoxia-induced transcriptional network in Mφ,
which is driven mostly by the hypoxia-induced factors (HIFs)
and NF-κB, the two master regulators of the hypoxic response.
We also draw attention to additional post-transcriptional, trans-
lational, and post-translational mechanisms that enable hypoxia
to activate or suppress gene and protein expression. Finally,
we review the relatively few studies on the mechanisms and
effects of hypoxia on differently activated Mo/Mφ, and discuss
how these mechanisms help shift the pro-inﬂammatory acti-
vated Mφ toward an anti-inﬂammatory, pro-angiogenic pheno-
type.
We do not expand on how hypoxia-induced mechanisms affect
the different Mφ functions, as these aspects were extensively
reviewed before (Lewis et al., 1999; Murdoch et al., 2004, 2008;
Bosco et al., 2008; Martinez et al., 2008; Coffelt et al., 2009; Walm-
sley et al., 2009; Qian and Pollard, 2010). Because the investigation
of mechanisms is most often performed in vitro, we limit our
discussion to these studies, and only brieﬂy mention the increas-
ing number of evidences pointing to the crucial role hypoxia
plays in vivo in the pathophysiology of many diseases. Moreover,
although hypoxia is physiologically and pathologically followed
by re-oxygenation, we focus only on the isolated effects of hypoxic
stress on Mo/Mφ. Likewise, the effects of reduced pH, low glu-
cose levels, or increased lactate, conditions that also accompany
hypoxia and ischemia, are not discussed.
DIFFERENT MODES OF MACROPHAGE ACTIVATION
Monocytes (Mo) migrate into tissues and differentiate into
Macrophages (Mφ) to perform many functions needed in the tis-
sue. These include resident Mφ that patrol their surroundings and
maintain homeostasis, Mφ that combat invading pathogens and
tumor cells and protect the tissue, Mφ that orchestrate the process
of wound healing, and Mφ that resolve inﬂammation. To perform
thesemultiple tasks,Mφphagocytose pathogens, secrete cytokines,
chemokines, and growth factors,present antigenic determinants to
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T cells and activate them, scavenge dead cells and necrotic debris
and deposit matrix proteins. Since one cell cannot perform all
these divergent tasks simultaneously, it was suggested that Mφ can
be differently activated, depending on the signals received from
the microenvironment. Thus, Mφ exhibit an enormous plasticity
(Stout and Suttles, 2004), and dynamically shift from one form of
activation to another according to the conditions in the chang-
ing microenvironment (Stout et al., 2009). This concept, as well
as the evidences supporting it and the markers that characterize
each Mφ phenotype, has been extensively reviewed (Mosser, 2003;
Martinez et al., 2008; Mosser and Edwards, 2008; Murdoch et al.,
2008; Gordon and Martinez, 2010; Qian and Pollard, 2010), and
will be only brieﬂy mentioned here.
In the continuum of Mφ phenotypes, two main sub-
populations have been described. In one extreme, the classically
activated Mφ, or M1 Mφ, is responsible for the multi-stage process
of recognizing pathogens, phagocytosing, and degrading them to
present their antigenic determinant to helper T cells in the con-
text of the MHC class II molecules, whose expression is elevated
(Mosser, 2003; Martinez et al., 2008). This process is accompanied
by secretion of IL-12,which is necessary to support aTh1 response.
M1 Mφ are activated by ligands of different receptor families such
as the toll-like receptor (TLR) ligands (e.g., lipopolysaccharides –
LPS), and pro-inﬂammatory cytokines (e.g., interferon-γ – IFNγ,
tumornecrosis factor-α–TNFα, and interleukin-1β– IL-1β). They
secrete high amounts of pro-inﬂammatory mediators that kill the
invading pathogens or tumor cells, such as the cytotoxic TNFα
and nitric oxide (NO), the latter (and the enzyme producing it,
inducible nitric oxide synthase – iNOS) serving as the hallmark
of this Mφ subset. They also secrete chemokines, which attract
more neutrophils andMo/Mφ to the inﬂamed site, thus amplifying
the pro-inﬂammatory response. Secretion of proteolytic enzymes,
such as matrix metalloproteinases (MMPs) helps degrade compo-
nents of the extracellular matrix (ECM) and allows migration of
leukocytes to the inﬂamed tissue.
In the other extreme we ﬁnd Mφ that are activated by and
secrete anti-inﬂammatory mediators (e.g., IL-10, IL-13, tumor
growth factor beta – TGFβ, and prostaglandin E2 – PGE2), which
generate a microenvironment that suppresses the activity of M1
macrophage. They remove cellular debris and performphagocyto-
siswhich ismediated by receptors different than those expressed by
M1 Mφ, such as the mannose receptor CD206; contribute to tissue
remodeling by depositing ECMproteins; and express high levels of
arginase-1,which produces ornithine, a precursor for the synthesis
of the ECM protein collagen. Arginase-1 also competes with iNOS
for their common substrate l-arginine and thus prevents NO pro-
duction. Thus, these alternatively activated or M2 Mφ are involved
mainly in homeostasis and wound healing. M2 Mφ also secrete
proteolytic enzymes that help them move about, and as they are
activated by IL-4 and IL-13, they are particularly suited to present
helminthes antigens to helper T cells and initiate a Th2 response
(Martinez et al., 2009), so that the term “anti-inﬂammatory”
refers, in fact, to a different type of inﬂammation.
A third subset of Mφ is responsible for immune regulation,
and may include several subtypes. Some of these cells are acti-
vated by ligands of TLRs in combination with immune complexes,
and some are activated by anti-inﬂammatory signals, such as
adenosine or phagocytosed apoptotic cells (Mosser, 2003; Mosser
and Edwards, 2008). Immature Mφ, which compose some of
the myeloid-derived suppressor cells (MDSCs) population, also
belong to regulatory Mφ. MDSCs are triggered by a combination
of IFNγ and IL-13, and secrete IFNγ, IL-13, IL-10, and TGFβ,
which help them suppress Th1 cell-mediated immune response,
induce regulatory T cells and inhibit M1 Mφ (Bronte, 2009;
Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha,
2009).
A different subset of Mφ isolated at the resolution-phase
of inﬂammation (resolution or rMφ) is often activated by
mediators released from apoptotic cells, such as sphingosine-1-
phosphate (S1P) or TGFβ. These rMφ secrete predominantly the
anti-inﬂammatory IL-10, very low levels of pro-inﬂammatory
cytokines and chemokines and express arginase-1 and CD206, as
well as the pro-inﬂammatory iNOS and COX-2 (Bystrom et al.,
2008). Moreover, in a model of self-resolving peritonitis, rMφ
were further divided into CD11bhigh and CD11blow cells (Schif-
Zuck et al., 2011). CD11bhigh rMφ engulf apoptotic neutrophils
and stay at the inﬂammatory site, where they express markers of
both M1 and M2 Mφ (e.g., iNOS, arginase-1, COX-2, and MMP-
9). However, once they engulf enough apoptotic cells (threshold
determined at 7 cells), they convert into CD11blow cells, induce
the expression of the enzyme 12/15-lipoxygenase which produces
pro-resolving lipid mediators, and emigrate to lymphoid organs to
convey resolution signals to lymphocytes (Schif-Zuck et al., 2011).
Collectively, all these regulatory Mφ, which secrete anti-
inﬂammatory mediators designed to resolve inﬂammation, are
positioned between M1 and M2 Mφ, and share markers with these
two sub-populations.
Malignant tumors are characterized by repeated cycles of
hypoxia and reoxygenation, and several Mφ subsets have been
found located in different regions of the tumor (Lewis and Pollard,
2006). These include the tumor-associated macrophages (TAMs)
and the Tie-2 expressing macrophages (TEMs), which support
tumor growth and metastasis, and are both an important source
of pro-angiogenic factors. Whereas some TEMs reside close to
blood vessels (peri-endothelial; Venneri et al., 2007), TAMs inﬁl-
trate deeper into the tumor and are located in perinecrotic areas
where oxygen tensions are very low.RegulatoryMDSCs are present
within tumors, as well as in lymphoid organs, such as the bone
marrow and spleen, and expand proportionally to the tumor bur-
den. All these subtypes share activation markers with both M2
and regulatory Mφ, thus placing them between these two subsets
(De Palma et al., 2007; Mosser and Edwards, 2008; Murdoch et al.,
2008). Of note, the principle of Mφ plasticity extends even to
TAMs subset, as they exhibit divergent phenotypes (Lewis and
Pollard, 2006), depending on the type of the tumor, the stage
of its development, the interactions with both the ECM and
other neighboring cells, and the level of oxygen tensions they are
exposed to.
Moving from Mφ to Mo, we ﬁnd the monocytes to have sim-
ilar but not identical classiﬁcations. Circulatory Mo are divided
into three subsets according to their CD14 and CD16 expression
(in humans) or Ly6C expression (in mice). The Classical or M1
Mo express high levels of CD14 and no CD16 (denoted either
CD14++CD16− or CD14+CD16− in human, and Ly6Chigh in
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mice), intermediate Mo, in humans only, express intermediate lev-
els of CD14 and CD16 (CD14++CD16+ or CD14+CD16+), and
resident, M2 or non-classical monocytes express very low levels of
CD14 andhigh levels of CD16 (CD14dimCD16+ orCD14−CD16+
in human, and Ly6Clow in mice) (Ziegler-Heitbrock, 2007; van de
Veerdonk and Netea, 2010). However, the function of these subsets
as cells secreting either pro- or anti-inﬂammatory cytokines is still
controversial. It is assumed that M1 and M2 Mo are the coun-
terparts of M1 and M2 Mφ, but this is not always accurate. For
example, sorted Mo subsets that were stimulated ex vivo with LPS
increased IL-10 secretion from CD14+CD16+ cells, whereas LPS-
stimulated CD14dimCD16+ cells showed increased TNFα with
little IL-10 secretion (Skrzeczynska-Moncznik et al., 2008). In a
different study, CD14−CD16+ cells showed patrolling character-
istics with weak ability for phagocytosis and low production of
ROS and cytokines when challenged by bacterial ligands of TLRs,
but secreted high amounts of the pro-inﬂammatory TNFα and
IL-1β cytokines upon stimulation with viral ligands or nucleic
acids (Cros et al., 2010). These results suggest that non-classical
or M2 Mo can behave as M1 Mo under certain circumstances.
Thus, Mo classiﬁcation does not fully match the M1-M2 Mφ
taxonomy.
During inﬂammation differently activated Mo/Mφ enter the
tissue, ﬁrst in order to eliminate pathogens or tumor cells (M1
Mo/Mφ), and later to heal the damaged tissue and to restore
homeostasis (M2 Mo/Mφ and rMφ; Nahrendorf et al., 2010). This
requires precise signals that regulate this sequential migration. For
example, the chemokines CCL2 and CX3CL1 and their receptors,
expressed on CD14+CD16− and both CD16+ monocytes, respec-
tively, were shown to mediate these responses (Geissmann et al.,
2003; Auffray et al., 2009). Of note, this speciﬁc sequence of events
may not always apply, and clinical scenarios which favor a Th2
responsemay differentially recruit non-classicalMo. Furthermore,
whether classically activated Mo mature to M1 Mφ in the tissue
and are later skewed to become M2 Mφ, or whether they die on
site and are replaced by newly recruited M2 Mo, remains unclear,
and the effects of the hypoxic microenvironment in this context
must be further explored.
According to the danger model (Matzinger, 2002), the direc-
tion and magnitude of the inﬂammatory response depend not
only on the nature of the stimulus (e.g., types of bacteria, site
of entry, size of the bacterial inoculation), but also on the type
and extent of expression of co-stimulatory molecules (e.g., CD80
vs. CD86) and speciﬁc signals received from the microenviron-
ment, such as danger-associated molecular patterns (DAMPs).
Necrotic and apoptotic cells that release their content into the
microenvironment, are picked up by Mo/Mφ, processed and
presented to T cells in the context of MHC class II and co-
stimulatory molecules. Thus, microenvironmental stimuli can
affect Mo/Mφ functions, directly or via their effect on other
cells.
These examples reveal the high plasticity of Mo/Mφ, and
emphasize that their heterogeneity ranges beyond the M1–M2
polarization models, and extends to new phenotypes we may yet
discover. Thus, Mo/Mφ classiﬁcation and the distinction between
their different activation modes and differentiation status is an
active area of study.
INFLAMMATION AND HYPOXIA
Low oxygen tensions (hypoxia) are relevant in many physiologi-
cal and pathological conditions. For example, hypoxia may arise
due to occlusion of a blood vessel (e.g., during myocardial infarc-
tion or pulmonary embolism), signiﬁcant blood loss or dilated
blood vessels which instigate reduced blood ﬂow and lack of
oxygen (e.g., in burns, trauma, and sepsis), or simply when oxy-
gen demands are not met (e.g., physical exercise, high altitudes,
tumors). Hypoxia has been demonstrated in vivo in a variety of
acute and chronic inﬂammatory sites, including the synovium in
RA patients, the arterial intima in atherosclerotic lesions, myocar-
dial infarcts, wounds, and sites of bacterial infection (reviewed in
Murdoch et al., 2005). Since even healthy tissues exhibit a wide
range of oxygen tensions, no one value can represent hypoxia, and
hypoxia is, therefore, functionally deﬁned as the inability of oxygen
delivery to meet oxygen demands of the tissue (Papandreou et al.,
2005). According to this deﬁnition, hypoxia occurs during inﬂam-
mation, as more cells that require oxygen inﬁltrate the site and
increase oxygen consumption, but only few capillaries can supply
it. Thus, different oxygen tensions can be measured in different
areas of tumors, wounds, or in tissues affected by chronic inﬂam-
mation, generating a gradient of hypoxia, where levels as low as
5–10mmHgweremeasured (Crowther et al., 2001). Of note, other
microenvironmental factors, such as increased lactate concentra-
tions and reduced pH, are linked to hypoxia, as they result from
the shift to anaerobic metabolism. Therefore, investigating the role
of prolonged hypoxia actually looks into the combined effect of
all of these stress factors. Most in vitro studies measure the percent
oxygen in the atmosphere ﬂowing into the hypoxic chamber, but
usually even in anoxic atmosphere (0% O2) some oxygen remains
dissolved in the medium (20–30mmHg).
Depending on its duration and severity, hypoxia can drive
inﬂammation and aggravate cellular and tissue injury. For exam-
ple,humans exposed to the scarce oxygen available inhigh altitudes
or mice exposed to ambient hypoxia experience reduced arter-
ial partial oxygen tensions, and develop pulmonary edema and
increased release of pro-inﬂammatory cytokines (Hartmann et al.,
2000; Grocott et al., 2009; Rosenberger et al., 2009). Hypoxia shifts
cells toward anaerobic metabolism, leading to exclusive use of gly-
colysis as the means for ATP production, instead of Krebs cycle.
As a result, lactate accumulates in the cells, causing cellular aci-
dosis, production of ROS is increased, and lipids are peroxidated
leading to membranal damage. This, combined with the lack of
ATP, impairs the function of ion channels, increases Ca+2 inﬂux,
and membrane permeability, leading to spillage of cellular content
(including proteolytic enzymes, hydrolases, and increased lactate),
thereby increasing acidosis and tissue damage (Minko et al., 2005;
Behn et al., 2007). Necrotic cells and increased tissue acidosis
recruit more leukocytes into the area, and trigger inﬂammation.
Hence, hypoxia and inﬂammation are interdependent, as chronic
inﬂammation is accompanied by hypoxia and prolonged hypoxia
leads to inﬂammation (Eltzschig, 2011).
ROLE OF HIFs
Like other cell types, the macrophage response depends on the
severity and the duration of the hypoxic insult. In recent years, the
search for the way cells sense differences in oxygen tensions was
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focused primarily on the prolyl hydroxylases (PHD)–HIF pathway
outlined below.
Hypoxia-induced factors are heterodimeric transcription fac-
tors consisting of a constitutively expressed β subunit (aryl hydro-
carbon nuclear translocator – ARNT), and an α subunit, which
is constitutively transcribed but immediately degraded in nor-
moxia. Three α subunits (HIF-1α, HIF-2α, and HIF-3α) have
been identiﬁed, which together with HIF-1β compose three iso-
forms that are differently expressed in various tissues.HIF-3α (also
called inhibitory PAS domain protein – IPAS) is a transcriptional
inhibitor and functions as a negative regulator of HIF-1α and
HIF-2α, although its biology is still unclear (Heikkila et al., 2011),
whereas HIF-1α and HIF-2α were more extensively studied. HIF-
1α and HIF-2α are homologous, especially in their DNA binding
domains, allowing their binding to the same hypoxia response
element (HRE).
The binding of HIF-1 and HIF-2 to many HRE-containing
promoters can induce the expression of a myriad of genes, some
with opposing effects. By means of over-expressing the HIF-α
subunits, or by ablating them in knockouts or by siRNA knock-
down, the role of each subunit in determining Mφ phenotypes
and response to hypoxic stress was established. Thus,HIF proteins
were shown to regulate all aspects of Mφ functions in response to
hypoxia, including the shift to anaerobic glycolysis, mitochondr-
ial impairment, angiogenesis, invasion, and immune suppression
(Coffelt et al., 2009; Walmsley et al., 2009; Werno et al., 2010a).
Moreover, HIFs are also induced in normoxia, and play a cen-
tral role in immune recognition, phagocytosis, bacterial killing,
and pro-inﬂammatory cytokine production (Cramer et al., 2003;
Peyssonnaux et al., 2007).
HIFs EXPRESSION IN DIFFERENT Mφ SUBSETS
The two HIF isoforms, HIF-1α and HIF-2α are differently
expressed in Mo and Mφ, as hypoxia could not induce the expres-
sion of HIF-1α or HIF-2α in human Mo, but did induce them in
humanmonocyte-derivedmacrophages (hMDM;Elbarghati et al.,
2008). Differentiated human and mouse MDM show different
kinetics of HIFs expression in response to hypoxia,with higher sta-
bility for HIF-2α expression (Elbarghati et al., 2008; Takeda et al.,
2010). This suggests that HIF-α subunits could, at least partially,
affect Mφ activation modes. Furthermore, arginine metabolism
was enhanced toward NO production in a HIF-1α-dependent
manner upon LPS or IFNγ stimulation, but NO production was
reduced by IL-4 due to increase in HIF-2α-induced arginase-1
activity (Takeda et al., 2010). Conﬂicting evidences show higher
accumulation of HIF-1α in hypoxic hMDM (Burke et al., 2002),
or higher expression of HIF-2α under similar conditions (Grif-
ﬁths et al., 2000). One study showed almost undetectable HIF-2α
mRNA after prolonged exposure to hypoxia, but induced HIF-
1α mRNA that was even further elevated by LPS in thioglycollate
(TG)-elicited peritoneal Mφ (Acosta-Iborra et al., 2009), whereas
another study showed constitutive HIF-2α mRNA levels in these
cells (Takeda et al., 2010). TAMs present in human breast car-
cinomas show high expression of HIF-2α, which correlates with
increased micro-vessel density and high tumor grade (Patel and
Simon, 2008). TAMs in different tumors in vivo show high expres-
sion of both HIF-1α and HIF-2α (Lewis and Pollard, 2006). The
importance of exposure time is demonstrated in a study that com-
pared acute (24 h) and chronic (5 days) exposures to hypoxia, and
reported that hMDM subjected to chronic hypoxia increased HIF-
1α and HIF-2α proteins relative to hMDM that were subjected to
normoxia or to acute hypoxia (Staples et al., 2010). However, there
is still no clear perspective regarding the role of the different HIFs
in hypoxic Mφ, and different periods of time of hypoxic expo-
sure or different oxygen levels may have different effects on HIFs’
expression.
REGULATION OF HIFs IN NORMOXIA AND HYPOXIA
Protein stability
Hypoxia-induced factor proteins are regulated primarily by pro-
tein stability. HIF-α subunits are constitutively transcribed and
translated, but immediately directed for degradation in normoxia.
This is achieved by the hydroxylation of proline residues (402 and
564 on HIF-1α and 405 and 532 on HIF-2α) by the three PHDs,
which depend on oxygen, 2-oxoglutarate, Fe+2, and ascorbate as
substrates and cofactors for their activity. Hydroxylation recruits
the von Hippel Lindau (VHL), which forms a complex together
with elongin B, elongin C, cullin-2, and ring-box 1 that has an E3
ubiquitin ligase activity. This complex ubiquinates HIF-α subunits
and targets them for proteosomal degradation (Nizet and John-
son, 2009; Walmsley et al., 2009). Hypoxia inactivates PHDs due
to the limited oxygen substrate, and therefore stabilizes the HIF-α
subunits, allowing their heterodimerization with the HIF-1β sub-
unit. Hypoxia also impairs electron transport in themitochondria,
leading to increased production of ROS, which oxidizes Fe+2 to
Fe+3 and further inhibit PHDs. Additional proteins contribute to
this regulation, and details on their activity are reviewed elsewhere
(Yee Koh et al., 2008).
Although HIF-α subunits are typically induced in hypoxia, they
can also be expressed in normoxia upon inﬂammatory stimu-
lation. For example, high levels of succinate (the product of 2-
oxoglutarate) or increased ROS production that oxidizes Fe+2 may
cause PHDs inactivation and HIF-1α stabilization (Denko, 2008).
Likewise, high concentrations of NO in normoxia can stabilize
HIF-1αby inhibiting the activity PHDs,probably by targeting their
Fe+2 catalytic site (Weigert and Brune, 2008). Ligation of TLRs,
such as the binding of LPS to TLR4, stimulate HIF-1α expression
in normoxia through the activity of NF-κB, and hypoxia in the
presence of LPS shows a synergistic effect (Frede et al., 2006).Addi-
tional pathways can contribute to HIF-1α expression, including
the Phosphatidylinositol 3-kinase (PI3K), Mitogen-activated pro-
tein kinases (MAPK) and theCa2+/calmodulin-dependent protein
kinases (CaMKII) pathways, and their inhibitors reduce HIF-1α
accumulation as well as the expression of its targets (Westra et al.,
2010). Thus, in addition to hypoxia, other stimuli, including bac-
terial infection, hormones, growth factors, cytokines, or RNS can
stabilize and activate HIF-1α in normoxia.
Translation and transcription of HIFs
The main known level of HIFs regulation is post-translational, as
described above. However other possible regulatory checkpoints,
such as transcription and translation, are under-investigated.
Although HIF-α subunits are constitutively transcribed in many
cell types, their mRNA levels are increased in hypoxia. HIF-1α
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promoter consists of Sp1 sites, several HRE sites (suggesting a
positive feedback loop), as well as NF-κB, Egr-1, and Stat3 binding
sites that mediate increased transcription in hypoxia (Niu et al.,
2008; Galban and Gorospe, 2009). Evidences show differences
between Mo and Mφ, as hypoxia inhibits HIF-1α transcription
in human Mo (Bosco et al., 2006), but increased HIF-1α mRNA
accumulation in hMDM by mechanisms other than increasing
mRNA stability (Staples et al., 2010). Likewise, HIF-1α mRNA
was increased during differentiation of THP-1 cells or peripheral
blood Mo into Mφ (Oda et al., 2006). This suggests a negative
feedback designed to control the systemic hypoxic response.
Translational regulation of HIFs is an important checkpoint
in both normoxia and hypoxia, which was investigated mainly in
cancer cells. Increased HIF-1α protein levels in hypoxia can be
observed without a parallel increase in the mRNA levels. This is
mediated by the binding of the two RNA-binding proteins (RBP)
polypyrimidine tract-binding protein (PTB) and human antigen
R (HuR) to the 3′-UTR and 5′-UTR, respectively, as their knock-
down through RNA interference inhibited HIF-1α accumulation
(Galban et al., 2008). Iron response proteins (IRP) bind to their
elements located in the 5′-UTR region of the HIF-2α mRNA
and inhibit translation of the mRNA in normoxia, while hypoxia
releases this binding and enhances HIF-2α translation (Galban
and Gorospe, 2009). Furthermore, speciﬁc microRNAs (the miR-
17-92 cluster and miR-199a) target HIF-1α mRNA in normoxia
and inhibit its translation, whereas hypoxia reduces their lev-
els and release HIF-1α mRNA translation (Galban and Gorospe,
2009). The mechanisms for translational controls have not yet
been described in Mo/Mφ, and this warrants more investigation.
Regulation of HIFs’ activity
Hypoxia-induced factors activity as transcription factors that bind
toHREs and to the co-activators CBP/p300 is regulated by oxygen-
dependent protein–protein interactions. Factor-inhibiting HIF-1
(FIH-1), another oxygen-dependent hydroxylase, can hydroxylate
asparagine residues onHIF-α subunits (803 onHIF-1α and 847 on
HIF-2α), resulting in proteins that cannot bind to the co-activators
CBP/p300 (Walmsley et al., 2008; Nizet and Johnson, 2009). Addi-
tionally, VHL also acts as an adapter that facilitates the binding
of FIH to HIF-α subunits in normoxia, while hypoxia disrupts
this interaction (Li et al., 2011), allowing for the accumulation
of HIFs and their binding to HRE-containing promoters. FIH-1
also plays a role in normoxia, as the cytoplasmic tail of MT1-
MMP/MMP-14 provides a platform to which both FIH-1 and its
inhibitor mint3/APBA3 bind. This limits the complex localiza-
tion to the Golgi apparatus and allows mint3 to inhibit FIH-1
ability to hydroxylate HIF-1α, resulting in enhanced accumula-
tion of HIF-1α in normoxia (Sakamoto and Seiki, 2010). It is yet
unclear whether a similar mechanism operates on PHDs local-
ization to render them inactive and inhibit HIFs degradation in
normoxic Mφ.
Post-translational modiﬁcations regulate stabilization, degra-
dation, and activity of HIF-α subunits by affecting their protein–
protein interactions, especially other transcription factors or com-
ponents of the transcriptional machinery. These were investigated
mostly in cancer cell lines and ﬁbroblasts. For example, HIF-α
is directly phosphorylated by the ERK1/2 MAPK, leading to its
transport to the nucleus and increased activity (Mylonis et al.,
2006). Two components of the PI3K/Akt pathway were shown
to oppositely regulate HIF-1α. The mTOR kinase phosphory-
lates HIF-1α in its oxygen-dependent degradation domain, lead-
ing to its increased stabilization and enhanced transactivation
(Hudson et al., 2002), whereas GSK-3-mediated phosphoryla-
tion induces HIF-1α destabilization and proteosomal degradation
(Flugel et al., 2007). Recently, PHD3 was found to hydroxylate
pyruvate kinase M2, leading to its enhanced interaction with both
HIF-1α and p300 in hypoxia and promoting their transactivation
of HRE-containing target genes (Luo et al., 2011).
Effects of HIF-1α S-nitrosylation are controversial, as it could
increase or decrease its ability to interact with its co-activator p300
(Sumbayev et al., 2003; Cho et al., 2007; Li et al., 2007). However,
this mechanism could be relevant only in normoxic induction of
HIF-1α, as iNOS is inactivated in hypoxia (see Intracellular Traf-
ﬁcking and Protein–Protein Interactions). Hypoxia was shown to
induce SUMOylation of HIF-1α, either promoting its binding to
VHL and degradation (Cheng et al., 2007) or promoting its sta-
bilization and transcriptional activity (Carbia-Nagashima et al.,
2007). These apparent contradictions may reﬂect use of differ-
ent cell types or different hypoxic regimes, and the effects of such
post-translationalmodiﬁcations in hypoxicMφ should be studied.
ROLE OF NF-κB
NF-κB are a family of proteins consisting of NF-κB1 (p105/p50),
NF-κB2 (p100/p52), RelA (p65), RelB, and c-Rel that can het-
erodimerize. The role of the NF-κB family members as master
regulators of many pro-inﬂammatory associated gene is widely
accepted (Vallabhapurapu and Karin, 2009).
NF-κB in different Mφ subsets
Canonical NF-κB activation is indispensible for M1 activation,
although cooperation with other transcription factors such as
Stat1 or the MAPK/AP-1 pathway is essential (Biswas and Lewis,
2010; Lawrence and Fong, 2010). NF-κB also regulates anti-
inﬂammatory and pro-angiogenic gene expression (e.g., IL-10,
VEGF, COX-2, TGFβ, and MMPs) and inhibits M1 Mφ (Lawrence
and Fong, 2010). In part, this is associated with over-expression of
p50 and formation of p50:p50 homodimers, which inhibit tran-
scription of pro-inﬂammatory cytokines while enhancing tran-
scription of anti-inﬂammatory genes (Saccani et al., 2006; Biswas
and Lewis, 2010; Mancino and Lawrence, 2010). Furthermore,
deletion of IKKβ in myeloid cells shifts Mφ toward M1 activa-
tion, increasing the expression of IL-12, MHC class II and iNOS,
and revealing the inhibitory role of IKKβ on Stat1 (Fong et al.,
2008).
Tumor-associated macrophages derived from human and
murine tumors and cultured in normoxia demonstrate defective
NF-κB activation, high IL-10 expression and reduced IL-12 and
TNFα production (Sica et al., 2000). However, as distinct regions
can be identiﬁed within solid tumors, TAMs could be activated
both as M1 and M2 Mφ and ﬂuctuate between them, depend-
ing on the type of the tumor, its stage, Mφ localization within
the tumor, and the signal received from the microenvironment,
including hypoxia (Mancino and Lawrence, 2010). Therefore, the
role of NF-κB in speciﬁc Mφ subsets is very complex.
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Regulation of NF-κB in normoxia and hypoxia – links to the HIF
pathway
Activation of NF-κB occurs in normoxia when TLRs or recep-
tors for pro-inﬂammatory cytokines recruit the MyD88 adapter
protein, which activates a complex signaling cascade that is based
on protein–protein interactions and culminates in the phospho-
rylation, ubiquitination, and degradation of IκB proteins and
translocation of NF-κB to the nucleus.
Hypoxia has long been shown to simulate NF-κB signaling.
In vivo, hypoxia activates NF-κB expression in a tissue-speciﬁc
manner, as transgenicmice harboring the luciferase gene under the
control of NF-κB expressed it in the hearts and lungs (Fitzpatrick
et al., 2011). In vitro there are many examples for hypoxia-induced
expression of pro-inﬂammatory genes. Hypoxic RAW 264.7 cells
induced MIP-2 expression, and inhibition of the ERK1/2 or PI3K
pathways decreasedp65 activity (Zampetaki et al., 2004). Increased
production of ROS due to hypoxia was demonstrated in Mo/Mφ
to be responsible for NF-κB activation and for the synergetic
effects of hypoxia and LPS (Chandel et al., 2000; Kim et al., 2010).
Recently, PDHs were demonstrated as regulators of NF-κB sig-
naling, as their inhibition suppressed LPS-induced expression of
TNFα in Mφ (Takeda et al., 2009). IKKβ was discovered as an
additional substrate that PDHs can hydroxylate, leading to its
activation and to IkB phosphorylation (Cummins et al., 2006).
Additionally, ankyrin repeats on both IκBα and the p105 subunit
of NF-κB can be hydroxylated by FIH-1 (Cockman et al., 2006;
Cummins et al., 2006; Frede et al., 2006), explaining the effect of
ROS on NF-κB activation. In fact, PDHs and FIH-1 involvement
in NF-κB regulation suggests that both HIF and NF-κB proteins
are redox-sensitive proteins regulated by the same oxygen sensors,
in addition to their role as master regulators of inﬂammation and
hypoxia.
Many hypoxia-induced genes are targeted by both NF-κB and
HIF proteins. Indeed, a link between the HIF and NF-κB pathways
is also provided by the presence of an NF-κB binding site in the
HIF-1α promoter (but not HIF-2α), and the ability of p50:p65
heterodimers to bind to it and drive its expression in hypoxia
(Belaiba et al., 2007), while siRNA for p65 inhibits this expres-
sion (Fitzpatrick et al., 2011). For example, COX-2 was induced
by hypoxia in a manner dependent on both HIF-1 and NF-κB
(Fitzpatrick et al., 2011), suggesting that the pro-inﬂammatory
response to hypoxia is regulated by NF-κB both by direct binding
to promoters of relevant genes and by inducing HIF-1α expression
(Fitzpatrick et al., 2011).
Mice lacking IKKβ show impaired accumulation of HIF-1α
both in hypoxia and upon bacterial infection (Rius et al., 2008),
demonstrating that NF-κB transcriptionally regulates HIF-1α in
both hypoxia and normoxia. In addition, a physical interaction
between IKKγ/NEMOandHIF-2α, but notHIF-1α, was described
to enhanceHIF-2α transcriptional activity in reporter assays (Patel
and Simon, 2008), but the speciﬁc gene targets remain unknown.
This link may be bidirectional, as prolonged hypoxia of hMDM
increased the mRNA expression and phosphorylation of the sev-
eral components in the NF-κB pathway (e.g., IKKβ, IKKγ, IkBα,
RelA/p65) in a manner that was dependent on both HIF-1α and
HIF-2α, as demonstrated by knocking down their expression using
siRNA (Fang et al., 2009).
INTERACTIONS WITH OTHER TRANSCRIPTION FACTORS
Hypoxia-induced factor and NF-κB can cooperate not only with
each other, but also with additional transcription factors in nor-
moxia and hypoxia, to achieve better target speciﬁcity or maximal
activity while forming a large protein complex at the promoters
of target genes. Activation of many transcription factors is man-
aged by the crosstalk between signaling pathways. For example,
ligation of TLRs or pro-inﬂammatory cytokines can recruit the
adapter protein MyD88 that activates both the IKK–NF-κB and
the MAPK pathways, leading to activation of NF-κB and AP-1.
The TRIF adapter protein may activate IRF3 and initiate delayed
expression of IFNβ, which activates Stat1 in an autocrine manner.
Cooperation between NF-κB, AP-1, Stat1, HIF-1, and HIF-2 is
required for M1 Mφ activation (Biswas and Lewis, 2010; Lawrence
and Fong, 2010). In contrast, anti-inﬂammatory cytokines (e.g.,
IL-4, IL-10, IL-13) activate Stat3 and Stat6, which are needed to
induce anti-inﬂammatory gene expression (e.g., arginase-1, sup-
pressor of cytokine signaling 3 – SOCS-3), and inhibit Stat1 and
NF-κB.
The integration of all the different microenvironmental signals
determines the balance between M1 and M2 activation modes,
suggesting a complex interplay between the transcription factors.
Thus, different combinations of transcription factors that coop-
erate on speciﬁc target promoters may determine the activation
phenotype of the Mφ (Biswas and Lewis, 2010; Lawrence and
Fong, 2010). Signal transduction is transient, and different path-
ways can be activated with different kinetics, and may inﬂuence
the complexity of the transcriptional network. This aspect war-
rants further study in differently activated Mφ. Table 1 details
some of the interactions between HIFs/NF-κB and several of the
central transcription factors that are induced in hypoxia.
TRANSCRIPTIONAL INHIBITION
Generally, HIF and NF-κB are considered activators of gene tran-
scription, although the NF-κB p50:p50 homodimers can be neg-
ative regulators, as mentioned above. Hypoxia can also selectively
inhibit gene transcription by other means. For example, in human
Mo hypoxia inhibited the constitutive expression of MCP-1/CCL2
mRNA and its induction by IFNγ and LPS by a dual mecha-
nism that included inhibition of transcription and enhancement
of mRNA destabilization (Bosco et al., 2004). As MCP-1/CCL2 is
a central chemoattractant for Mo, its inhibition may represent a
negative regulatory mechanism that controls recruitment of M1-
activated Mo/Mφ into inﬂamed tissues. In support of this ﬁnding,
hypoxia can also inhibit gene expression of CCR5, cathepsin C,
2.5-oligoadenylate synthetase, and the Ras family member Rab7
(Bosco et al., 2006). TIMP-2, the endogenous inhibitor of MMPs,
is constitutively expressed in Mo, and hypoxia down-regulates it
through the involvement of Sp1 phosphorylation (Lahat et al.,
2011).
Surprisingly, in several cases HIF-1 plays a role as a sup-
pressor. In ﬁbroblasts and epithelial cells HIF-1α was impli-
cated in the down-regulation of anti-angiogenic targets such as
thrombospondin-1 (Laderoute et al., 2000) and the reversion-
inducing cysteine-rich protein with Kazal motifs (RECK) together
with histone deacetylase 1 (HDAC1; Lee et al., 2010). In Mφ,
the scavenger receptor MRS1 was down-regulated in hypoxia.
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Table 1 |Transcription factors other than HIFs and NF-κB, which are involved in hypoxic regulation of gene expression.
TF General, function Induction/activation Hypoxia stimulates Cooperation with
AP-1 Heterodimers of the c-Jun,
c-Fos, and ATF families
TLR ligation via MAPK
activation
Increased Fos-2, Fra-2. Acti-
vated by JNK
HIF-1, NF-κB
Egr-1 Zinc-ﬁnger factor, regulates Mo
differentiation and mitogenic
responses
Growth factors Ligation of RAGE receptor,
involving PKCβII and JNK acti-
vation
HIF-1 and C/EBPα. Also binds to
HIF-1α promoter
Stat1 Regulates immune recognition
(e.g., MHC class II,
co-stimulatory molecules)
IFNα/β, IFNγ Both increased and repressed
expression were observed
NF-κB and C/EBPβ
Stat3 Regulates typical M2-Mφ
activation genes (e.g.,
arginase-1 and -2, SOCS-3)
IL-6, IL-10 Increased phosphorylation
and activation
NF-κB and HIF-1, but also inhibits
IKKβ and opposes NF-κB; key
player in M1 to M2-Mφ shift
Stat6 Regulates typical M2-Mφ
activation genes (e.g.,
arginase-1, arginase-2, SOCS-3)
IL-4, IL-13 ND ND
C/EBPβ
(NF-IL-6)
Heterodimer with C/EBPα/γ/δ.
Regulates genes of acute
phase response, Mo
differentiation, IL-12, iNOS, and
arginase-1
LPS, IL-6, IFNγ. Constitutively
expressed in Mφ
ND NF-κB for IL-6 production
C/EBPα Homodimer or heterodimer
with C/EBPβ/γ
Growth hormone, IGF-1 via
ERK1/2 and GSK3
Suppressed expression by
HIF-1α
HIF-1α and Egr-1. Also opposes
HIF-1α by competing with HIF-1β
for its binding
Studies involving the transcription factors indicated were conducted mostly in tumor cell lines and require conﬁrmation in Mo/Mφ.
References pertaining to the transcription factors mentioned are: AP-1 (Bandyopadhyay et al., 1995; Alfranca et al., 2002; Laderoute, 2005; Bosco et al., 2006; Mancino
and Lawrence, 2010); Egr-1 (Liao et al., 2007; Sperandio et al., 2009; Xu et al., 2010); Stat1 (Lee et al., 2006; Ivanov et al., 2007; Sow et al., 2009); Stat3 (Sica et al.,
2008; Hagemann et al., 2009; Noman et al., 2009; Grivennikov and Karin, 2010; Kang et al., 2010); Stat6 (Hagemann et al., 2009); C/EBPβ (Dlaska andWeiss, 1999;
Gorgoni et al., 2002; Albina et al., 2005; Elbarghati et al., 2008); C/EBPα (Liao et al., 2007; Janardhan, 2008; Yang et al., 2008).
TF, transcription factor; ND, not determined.
Over-expression of HIF-1α suppressed MSR1 mRNA expres-
sion, and or its depletion by siRNA restored MSR1 expression,
demonstrating the ability of HIF-1 to convey transcriptional
inhibition (Shirato et al., 2009). Furthermore, hypoxia was able
to suppress gene expression indirectly through HIF-1α, as it
induced the expression of the transcription repressor BACH1,
which regulates the expression of heme oxygenase-1 in human
primary monocytes (Bosco et al., 2006). However, the mecha-
nisms that allow HIF-1α to play a dual role as both an activator
and suppressor are not yet known, and this needs to be further
explored.
POST-TRANSCRIPTIONAL MECHANISMS OF HYPOXIC
REGULATION
ALTERNATIVE SPLICING AND mRNA STABILITY
Like many other genes, the murine HIF-1α mRNA is alterna-
tively spliced, generating the HIF-1αI.1 and HIF-1αI.2 isoforms,
which have alternative ﬁrst exons and promoters. Stimulation of
TG-elicited peritoneal Mφ and RAW 264.7 cells with TLR4 and
A2AR agonists synergistically increased the expression of both
isoforms with different kinetics. However, only HIF-1-αI.1 was
involved in cytokine production and down-regulated the LPS-
induced production of pro-inﬂammatory cytokines (e.g., TNFα,
IL-1β, IL-6, IL-12p40, MIP-1α, MCP-1, and MIP-2), but not IL-1
orVEGF, as was demonstrated in HIF-1αI.1−/− cells. Hypoxia had
no effect on the expression of both isoforms (Ramanathan et al.,
2009).
The only case that we are aware of hypoxia-induced alternative
splicing is of CD80, where hypoxia reduced its surface expression
on RAW 264.7 cells while increasing the concentrations of the
soluble protein in the supernatants. As ampliﬁcation of the total
mRNAcoding forCD80 remainedunchanged,but themRNAcod-
ing for the transmembranal region was reduced, it was concluded
that hypoxia triggers alternative splicing to generate soluble CD80
(Lahat et al., 2003).
Stability of mRNAs is mediated through the AU-rich elements
(AREs) located on the 3′-UTRs of many labile mRNAs and their
interaction with different RBP. Presence of AREs is often corre-
lated with rapid mRNA degradation, as occurs with many pro-
inﬂammatory genes such as cytokines (e.g., TNFα,GM-CSF, IL-8),
growth factors (e.g., VEGF), transcription factors (e.g., HIF-1α),
and other genes (e.g., iNOS, COX-2, uPA, MMPs; Khabar, 2010).
Efﬁcient AREs consist of overlapping repetitions of the pentamer
AUUUA, giving rise to one or several UUAUUUAUU nonamers,
and can assume either a linear or a stem-and-loop conformation.
The length of the 3′-UTR and of the ARE itself affects mRNA sta-
bility, and longer AREs are associated with shorter half-lives of the
mRNAs.
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Several RBPs bind to 3′-UTR AREs and target the mRNAs
for degradation, including tristetraprolin (TTP) and K-homology
splicing-regulatory protein (KSRP), while the HuR promote their
stabilization. HuR is mostly a nuclear protein, which upon stim-
ulation translocates to the cytoplasm where it binds to selected
mRNAs and stabilizes them. Alternatively, phosphorylation of
TTP and KSRP reduce their afﬁnity to AREs and thus stabilize
the mRNA. In its unphosphorylated form, TTP recruits factors
that mediate decapping, deadenylation, and mRNA destruction.
Thus, there is a complex interplay between RBPs that bind to the
AREs and determine the mRNA half-life (Khabar, 2010).
The 3′-UTR of the HIF-1α mRNA contains six scattered pen-
tamer AREs and one nonamer ARE, suggesting that TTP could
bind to theHIF-1α 3′-UTR and regulate its stability. In several can-
cer cell lines, hypoxia increased TTP expression, and the protein
directly bound to the HIF-1α mRNA AREs. Consistently, over-
expressionof TTP resulted indecreasedHIF-1αmRNA,suggesting
that hypoxic cells use TTP to modulate HIF-1α expression (Shin
et al., 2010). Although this was not tested in Mo/Mφ, another
study demonstrated that prolonged hypoxia and LPS increased the
expression of the dephosphorylated form of TTP in RAW 264.7
cells, and reduced the stability of TNFα, IL-6, MIP-2, and GM-
CSF. Knock-down of TTP by siRNA abolished this destabilization
(Werno et al., 2010b). On the other hand, the expression of CXCR4
mRNAwas stabilized in hypoxia, although themechanismwas not
studied (Schioppa et al., 2003).
TRANSLATIONAL REGULATION: RIBOSWITCHES AND microRNAs
Hypoxia leads to immediate shut-down of general protein trans-
lation. However, selected proteins, including the HIF proteins and
their targets, are nonetheless translated. How these proteins escape
global inhibition of translation remains unclear.
Translational regulation is achieved by severalmechanisms, and
structural elements in the non-coding regions of messenger RNA
were shown to modulate gene expression. An example of such an
element is the riboswitch, a regulatory element that binds small
molecules or ribonucleicprotein (RNP) complexes that induce its
conformational change. Riboswitches are usually identiﬁed in bac-
teria, but recently a similar element was identiﬁed in the VEGF-A
mRNA. This transcript is equally transcribed in IFNγ-induced
U937 cells in normoxia and hypoxia, but the protein translation
is inhibited after 24 h in normoxia, whereas hypoxia abolishes this
effect (Ray et al., 2009). The VEGF-A transcript contains a 126-
nt ARE called hypoxia stability region (HSR) that mediates the
mRNA stability in hypoxia. It includes two cis-elements, one is a
21-nt CA-rich element (CARE) that binds with high afﬁnity to the
heterogeneous nuclear ribonucleoprotein L (hnRNP L), and the
other is a 29-nt IFNγ-activated inhibitor of translation (GAIT)
element that binds the GAIT complex and silences inﬂammatory
gene expression. The binding to these two elements is mutually
exclusive. Thus, in normoxia IFNγ stimulates the binding of GAIT
complex to its element, thereby silencingVEGF-A gene expression,
whereas in hypoxia the HSR undergoes a conformational change,
which favors binding of hnRNP L and overrides the suppressive
effects of IFNγ and the GAIT complex (Ray et al., 2009).
Additional translational regulation is exerted by microRNAs
(miRNAs), small non-coding RNA molecules that bind with
imperfect complementarity to speciﬁc mRNA target sequences,
usually located in the 3′-UTR of target mRNA, and rapidly and
reversibly inhibit their translation. As miRNA are usually inde-
pendently transcribed, and some contain HRE in their promoter,
hypoxic stress can stimulate their transcription, as was shown in
different cell types (Pocock, 2011). For example, miR-210 whose
promoter contains an HRE is induced in hypoxic tumor and
endothelial cells, and can bind to target genes that are crucial in
the mitochondria electron transport, thus diverting the cells away
from oxidative phosphorylation and toward glycolysis. Alterna-
tively, miR-210 can repress normoxic target genes that are not
required for the hypoxic response (Pocock, 2011).
In Mo/Mφ several miRNAs were identiﬁed as regulators of
the inﬂammatory response, in particular miR-155 (O’Connell
et al., 2007), miR-146a, and miR-132 (Taganov et al., 2006). LPS
markedly induced miR-146a expression in Mo/Mφ in a prolonged
kinetics, and negatively regulated IRAK-1 and TRAF-6 expression
leading to down-regulation of theNF-κBpathway, as well as to LPS
tolerance and cross tolerance (activation by other TLR ligands) in
LPS-primed Mo/Mφ (Nahid et al., 2009, 2011).
H2O2-induced oxidative stress in RAW 264.7 Mφ activated the
NF-κB pathway and down-regulated the expression of a unique
set of miRNA∗s (miRNA expressed at low levels relative to the
miRNA in the opposite arm of a hairpin; i.e., miR-27a∗, miR-
27b∗, miR-29b∗, miR-24-2∗, and miR-21∗), implicating them, and
miR-27b∗ in particular, in NF-κB regulation (Thulasingam et al.,
2011). Regulation by both miRNA and RBPs is primarily exe-
cuted on the 3′-UTR region in overlapping sequences, indicating
possible crosstalk. Indeed, the translation of VEGF-A mRNA is
inhibited by the binding of several miRNAs to the CARE, particu-
larly miR-297 and miR-299 in normoxic monocytic cells (even
without additional stimulation with IFNγ). However, hypoxia
induces translocation of hnRNP L to the cytoplasm,where it binds
theVEGF-A mRNA and prevents miRNA silencing (Jafarifar et al.,
2011).
Regulation of protein translation by miRNAs is even further
complicated by the ﬁnding that miRNA can oscillate between
translational repression and activation (which is distinct from
alleviating translational repression), depending on their binding
location and/or on the conditions in the microenvironment. For
example, in proliferating cells TNFα translation is inhibited by the
binding of miRNAs to its ARE located in the 3′-UTR. However,
upon serum-starvation and cell cycle arrest, HEK293 cells up-
regulated TNFα-ARE expression in a manner that depended on
miR-369-3. This wasmediated by the increased expression of miR-
369-3, which recruited the fragile X mental retardation-related
protein 1 (FXR1), found exclusively in the activating complex,
and Ago2, found in both repressing and activating complexes,
into a complex that executed translation activation (Vasudevan
et al., 2007). However, as TNFα is mainly produced in Mo/Mφ,
and its 3′-UTR ARE is representative of other pro-inﬂammatory
cytokines with short half-life, it is very important that these results
be conﬁrmed in Mo/Mφ cells, and the precise microenvironmen-
tal conditions that activate this switch be deﬁned. These results
suggest a new multi-input signal integration mechanism, which
could be advantageous particularly in Mo/Mφ that must adapt to
the changing microenvironment.
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INTRACELLULAR TRAFFICKING AND PROTEIN–PROTEIN INTERACTIONS
The ability of Mo/Mφ to migrate through the ECM is mediated
by the balanced secretion of different MMPs, particularly MMP-9,
and their endogenous inhibitors TIMPs. Hypoxia inhibits migra-
tion of human monocyte-derived dendritic cells by disrupting
this balance, as TIMP-1 was increased whereas MMP-9 and MT1-
MMP were decreased (Qu et al., 2005). These inhibitory effects of
hypoxia may have been mediated by the adenosine receptor A2B in
a cAMP and PKC dependent manner (Zhao et al., 2008). Hypoxia
also inhibited the TNFα-induced secretion of MMP-9 from U937
cells and primary Mo, thus markedly inhibiting their migration
(Rahat et al., 2006). This was not regulated at the transcriptional
level, as MMP-9 mRNA was unchanged, or at the translational lev-
els, as the amounts of the intracellular enzyme were increased in
hypoxia. Instead, confocal microscopy revealed that in hypoxia
MMP-9 was attenuated in secretory vesicles due to the effects
of hypoxia on the cytoskeleton. Indeed, secretion of proMMP-
9 was reduced by the addition of cytochalasin B or nocodazole,
which inhibits the polymerization of actin and tubulin ﬁbers, or
by the addition of the Rho kinase inhibitor Y27632, suggesting
the involvement of the cytoskeleton and the Rho GTPases in the
process of enzyme secretion (Rahat et al., 2006).
Reduced MMP-9 in hypoxia could explain the immobilization
of Mo/Mφ in hypoxic regions, in addition to other mechanisms
that were reviewed elsewhere (Murdoch et al., 2004; Bosco et al.,
2008). Another example of intracellular trafﬁcking is mentioned
later (see TNFa Trafﬁcking).
The hallmark of M1-activated Mφ is iNOS expression and high
NO production, which is crucial for the killing abilities of the
Mφ, whereas low levels are considered pro-angiogenic (Weigert
and Brune, 2008). The main regulatory checkpoint for iNOS is
transcriptional, and NF-κB, IRF-1, Stat1, HIF-1α, and C/EBPβ
are implicated in its regulation (Pautz et al., 2010). In hypoxia,
induction of iNOS transcription and protein expression is demon-
strated in differently activated Mφ (e.g., peritoneal TG-elicited
Mφ, wound Mφ, spleen Mφ). However, the enzyme is inactivated
and may produce only very low amounts of NO (Melillo et al.,
1996; Daniliuc et al., 2003). This inactivation was attributed to
the lack of the oxygen substrate during hypoxic stress, however,
hypoxic Mφ lysates failed to produce NO in an a-cellular system
in normoxia, where all cofactors and substrates were abundantly
present, suggesting a more intricate regulation. Further investiga-
tion revealed that in normoxia iNOS is associatedwithα-actinin-4,
a protein responsible for the cross-linking of actin ﬁbers. This
interaction recruits iNOS to the sub-membranal area and ensures
its activity.However,hypoxia disrupts these interactions, interferes
with iNOS localization and causes its inactivation (Daniliuc et al.,
2003).
These two examples highlight a special role for the cytoskeleton
in regulating enzyme activity and Mφ phenotype. As cytoskele-
ton ﬁbers are responsible for the cellular protein trafﬁcking, their
disruption may attenuate vesicles within the Mφ and prevent
secretion of their content, or inhibit delivery of proteins to their
destination. For example, hypoxia increased tubulin stabilization
and changed vesicle trafﬁcking in breast carcinoma cells (Yoon
et al., 2005). This is further supported by recent ﬁndings linking
actin cytoskeleton to HIF-1α stability (Shin et al., 2010).
THE EFFECTS OF PREVIOUS Mφ ACTIVATION ON THE HYPOXIC
STIMULATION – THE TNFα EXAMPLE
TNFα TRAFFICKING
In addition to the MMP-9 example, where hypoxia attenuated
secretory vesicles, hypoxia also affects TNFα transport. In TG-
elicited peritoneal Mφ and in RAW 264.7 cells, hypoxia did not
change the LPS-induced TNFα mRNA levels relative to normoxia,
whereas the membranal and intracellular amounts of the protein
were reduced, suggesting degradation of TNFα. The proteososmal
inhibitor MG132 did not change the hypoxic down-regulation
of TNFα, whereas the lysosome inhibitor baﬁlomycin A1 dose-
dependently inhibited degradation of intracellular TNFα, sug-
gesting that TNFα is degraded at the lysosome. Using several
Rab proteins as markers for different vesicles, TNFα trafﬁcking
was mapped to the endosomal pathway, and its presence was
demonstrated in recycling endosomes, early endosomes, lysosome,
and secretory lysosomes. The increased hypoxic co-localization
of TNFα and LAMP-1, the lysosome marker, and the ability of
baﬁlomycin A1 to increase intracellular TNFα to normoxic values,
suggested that TNFα is directed to the lysosome and that hypoxia
enhances its degradation (Lahat et al., 2008).
EFFECTS OF PREVIOUS Mφ ACTIVATION ON THE HYPOXIC
STIMULATION
The overall effects of hypoxia on the expression of TNFα are con-
troversial. It is widely accepted that hypoxia and LPS increase Mφ
TNFα secretion (Table 2). However, in some cases hypoxia can
inhibit TNFα secretion. In our own hands hypoxia exerted oppos-
ing effects on LPS-induced secretion of TNFα, as it enhanced it
from human monocytes (Lahat et al., 2003), but down-regulated
its secretion from peritoneal TG-elicited Mφ and RAW 264.7 cells
(Lahat et al., 2008). We have demonstrated that hypoxia enhances
the lysosomal degradation of TNFα, thus causing its reduction in
pro-inﬂammatory induced RAW 264.7 cells (Lahat et al., 2008).
Werno et al. (2010b) have also shown that hypoxia reduced TNFα
secretion from pro-inﬂammatory RAW 264.7 cells, although they
suggested a mechanism of reduced mRNA stability, which also
affected other pro-inﬂammatory mediators such as MIP-2 and
IL-6, and is not mutually exclusive with lysosomal degradation.
This apparent contradiction between the enhancing and
inhibiting effects of hypoxia onTNFα secretionmay be resolved by
taking into account the priming state of the Mφ. Priming signals
may by themselves be insufﬁcient to stimulate Mφ, but they sen-
sitize it for further triggering. Traditionally, IFNγ is used to prime
Mφ that consequently encounter TLR ligands (such as LPS) and
become fully M1 activated, although the sequence of these events
is insigniﬁcant (Schroder et al., 2006). We suggest that “naïve”
Mφ that were not previously primed respond to a combination
of hypoxia and LPS by elevating TNFα secretion, whereas Mφ
that are already primed or M1-activated react by down-regulating
TNFα secretion, relative to activation with LPS alone. In this sense,
RAW 264.7 cells behaved like primed cells, and we speculate that
as the cell line was obtained from a tumor induced by the Abel-
son murine leukemia virus, the viral transformation primes the
macrophage.
To further make the point, we compared resident peritoneal
Mφ with TG-elicited Mφ, by exposing them for 48 h to hypoxia,
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Table 2 | Controversial effects of hypoxia onTNFα secretion from Mφ.
Mφ type Priming Hyp. (%) Time (h) Stim. Mechanism Effect Reference
NAïVE MO/Mφ
Human Mo None <0.3 24 LPS Transcription Up-regulation Lahat et al. (2003)
None 3 16 LPS Transcription Up-regulation Guida and Stewart (1998)
None 1 None Transcription Up-regulation Demasi et al. (2003)
Resident
peritoneal Mφ
None <0.3 24 LPS Transcription Up-regulation Lahat et al. (2003)
None 0 18 LPS Transcription Up-regulation Meng et al. (2001)
None 0 24 LPS+ IFN Transcription Up-regulation Albina et al. (1995)
Alveolar Mφ None 2 2 LPS Transcription Up-regulation Leeper-Woodford and Detmer (1999)
Wound Mφ None 0 24 LPS+ IFN Transcription Up-regulation Albina et al. (1995)
BV-2 microglial
cells
None 3 12 None Transcription Up-regulation Li et al. (2009)
THP-1 None 1 18 None Transcription Up-regulation Scannell et al. (1993)
PRIMED MO/Mφ
RAW 264.7 (Viral) trans-
formation?
16 LPS mRNA stability Down-
regulation
Werno et al. (2010b)
24 None Not speciﬁed Down-
regulation
Yun et al. (1997)
<0.3 24 LPS Enhanced lysosomal
degradation
Down-
regulation
Lahat et al. (2008)
TG-elicited
peritoneal Mφ
TG <0.3 24 LPS Enhanced lysosomal
degradation
Down-
regulation
Lahat et al. (2008)
Stim., stimulus; Hyp., hypoxia.
with or without addition of LPS. Figure 1 shows the opposing
effects of hypoxia on these Mφ, although they originate from the
same organ. Given the wide use of TG-elicited Mφ, it is impor-
tant to note that these cells are derived from a site of ongoing
inﬂammation, and are therefore at least partially activated and
should be considered primed in comparison to the“naïve”resident
peritoneal Mφ (as stated in Takeda et al., 2010).
Likewise, when we primed U937 or THP-1 cells by incubating
them or 48 h with LPS (simulating gram negative bacterial activa-
tion) or with IFNβ (simulating viral activation), and then exposed
them for additional 24 h to LPS (at a higher concentration) and
hypoxia, we again observed the inhibitory effects of hypoxia on
IFNβ-primed cells, but not on “naïve” cells (Figure 1). Note that
the lack of response when cells were primed with LPS suggests the
involvement of LPS tolerance, which is mediated by the NF-κB
p50:p50 homodimers (Frede et al., 2009). It may also imply that
IFNβ-priming is mediated by a different mechanism. Thus, the
inhibited secretion of TNFα, a typical pro-inﬂammatory marker,
from primed M1-activated Mφ is inhibited by hypoxia, suggesting
that hypoxia may act to restrain the pro-inﬂammatory Mφ.
CONCLUDING REMARKS AND PERSPECTIVES
Generally, the hypoxic response depends on cell type, duration of
exposure, severity of the hypoxic insult, and as demonstrated for
TNFα, previous priming of the Mφ. Thus, hypoxia can activate
Mφ in a pro-inﬂammatory way, or skew the pro-inﬂammatory
Mφ toward a phenotype approximating the M2 or resolution phe-
notypes. Since hypoxic Mφ display a mixture of markers of both
M1 andM2 activation, classifying them is not straightforward, and
they may represent a unique mode of activation which has several
commonmarkers with bothM1 andM2 activation. In this respect,
hypoxia may serve to restrain the pro-inﬂammatory Mφ and pre-
vent exacerbationof tissue damage,or alternatively ensure thatMφ
retained in the hypoxic tissue for long periods of time can gradu-
ally become M2 activated and engage in processes such as wound
healing and/or resolution. In physiological scenarios (e.g., acute
inﬂammation) this has a favorable outcome, whereas in chronic
inﬂammation (e.g., in autoimmune diseases or solid tumors) the
inhibitory effects of hypoxia may have devastating results.
Hypoxia profoundly changes Mo/Mφ activation mode by regu-
lating gene expression. Most of the known regulatory mechanisms
are transcriptional, and rely on the cooperation between the mas-
ter regulator NF-κB and HIFs to mediate this induction of gene
expression. However, in some cases HIF can also act as a transcrip-
tional suppressor. Determination of Mφ activation mode further
rely on the cooperationwith additional transcriptional factors that
are expressed or modiﬁed according to the signals received by
the microenvironment. The effects of hypoxia on differently acti-
vated Mφ and the molecular mechanisms it exerts (summarized in
Figure 2) were not investigated enough. For example, it seems rea-
sonable to assume that differently activated Mφ located in diver-
gent microenvironments would express different HIF isoforms in
different proportions and with different kinetics. However, this
assumption merits further study.
Additional levels of post-transcriptional and post-translational
regulation are gradually revealed. These include regulation of
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FIGURE 1 | Priming of Mφ affects the hypoxic response. (A) Resident
peritoneal Mφ (n=14) or (B)TG-elicited peritoneal Mφ (n=16) were
subjected to hypoxia (<0.3% O2) for 24 h, with or without stimulation with
LPS (1μg/ml). Hypoxia inhibited the secretion of high amounts of TNFα
that were produced in normoxia in primedTG-elicited Mφ, while an
opposite response to hypoxia was observed for the naïve resident Mφ. The
human monocytic cell lines (C) U937 (n=12) and (D)THP-1 (n=18) were
primed with either LPS (100 ng/ml) or IFNβ (10U/ml) for 48 h in normoxia,
before LPS (1μg/ml) was added and cells were incubated for additional
24 h in normoxia or hypoxia. Hypoxia increasedTNFα secretion in naïve
Mo, but inhibited it in IFNβ-primed cells. TNFα was determined in the
supernatants using ELISA.
FIGURE 2 | Molecular mechanisms mediating the regulatory effects of
hypoxia. Hypoxia affects the production, secretion, and activity of key Mφ
proteins in several regulatory checkpoints, generally keeping the
pro-inﬂammatory Mφ in check. (A)Transcriptional regulation in the
M1-activated Mφ in normoxia is based on the collaboration between
NF-kB, low level of HIF-1, and additional transcription factors. In hypoxia,
more HIFs are produced, and genes involved in angiogenesis, metabolism,
and survival are triggered. (B) HIFs protein stability in hypoxia is increased,
as the prolyl hydroxylases that target them for proteosomal degradation in
normoxia are inhibited. (C) Stability of mRNA is regulated by RNA-binding
proteins to the AU-rich elements (ARE) located in the 3′-UTR. (D)
Post-transcriptional regulation – Riboswitch: The VEGF example illustrates
how hypoxia changes secondary structures of 3′-UTR elements, and the
binding of protein complexes to them, thus increasing their stability and
translation. (E) Post-transcriptional regulation – microRNAs: Hypoxia
modulates the expression of microRNAs that bind selected transcripts,
thereby inhibiting or alleviating inhibition of their translation. (F)
Post-translational regulation – Trafﬁcking: Hypoxia retains secretory
vesicles by inhibiting the actin cytoskeleton, thus attenuating the secretion
of proteins such as MMP-9. Hypoxia also enhances the lysosomal
degradation of other proteins, such asTNFα, which are secreted via the
endosomal pathway. (G) Post-translational regulation – Localization:
Hypoxia disrupts the interactions between iNOS and α-actinin-4, which
anchors it to the cortical cytoskeleton, resulting in its inactivation. SV,
secretory vesicles; EE, early endosomes; L, lysosome; SL, secretory
lysosomes. +/− indicated reduced or inhibited transcription.
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mRNA stability, regulation of translation via RBP and microRNA,
protein trafﬁcking and protein–protein interactions which may be
regulated via reorganization of the cytoskeleton. We now begin
to understand how some of these mechanisms allow Mφ to inte-
grate the different microenvironmental signals and to determine
the Mφ activation mode. Therefore, these mechanisms should be
further studied in the context of Mφ activation, to provide bet-
ter insights and new approaches to manipulate Mφ in the hypoxic
microenvironment while taking advantage of their selective ability
to home to and accumulate in hypoxic regions.
ACKNOWLEDGMENTS
This work was supported by a grant from the Rappaport Fam-
ily Institute for Research in the Medical Sciences and by Research
Grant 5343 from the Chief Scientist Ofﬁce of the Israeli Ministry
of Health. We would like to thank Amir Rahat for critical reading.
REFERENCES
Acosta-Iborra, B., Elorza, A., Olaza-
bal, I. M., Martin-Cofreces, N. B.,
Martin-Puig, S., Miro, M., Calzada,
M. J., Aragones, J., Sanchez-Madrid,
F., and Landazuri, M. O. (2009).
Macrophage oxygen sensing mod-
ulates antigen presentation and
phagocytic functions involving IFN-
gamma production through the
HIF-1 alpha transcription factor. J.
Immunol. 182, 3155–3164.
Albina, J. E., Henry, W. L. Jr., Mas-
trofrancesco, B., Martin, B. A., and
Reichner, J. S. (1995). Macrophage
activation by culture in an anoxic
environment. J. Immunol. 155,
4391–4396.
Albina, J. E., Mahoney, E. J., Daley,
J. M., Wesche, D. E., Morris, S.
M. Jr., and Reichner, J. S. (2005).
Macrophage arginase regulation by
CCAAT/enhancer-binding protein
beta. Shock 23, 168–172.
Alfranca, A., Gutierrez, M. D., Vara, A.,
Aragones, J.,Vidal, F., and Landazuri,
M. O. (2002). c-Jun and hypoxia-
inducible factor 1 functionally coop-
erate in hypoxia-induced gene tran-
scription. Mol. Cell. Biol. 22, 12–22.
Auffray, C., Sieweke, M. H., and Geiss-
mann, F. (2009). Blood mono-
cytes: development, heterogeneity,
and relationship with dendritic
cells. Annu. Rev. Immunol. 27,
669–692.
Bandyopadhyay, R. S., Phelan, M., and
Faller, D. V. (1995). Hypoxia induces
AP-1-regulated genes andAP-1 tran-
scription factor binding in human
endothelial and other cell types.
Biochim. Biophys. Acta 1264, 72–78.
Behn, C., Araneda, O. F., Llanos, A.
J., Celedon, G., and Gonzalez, G.
(2007). Hypoxia-related lipid perox-
idation: evidences, implications and
approaches. Respir. Physiol. Neuro-
biol. 158, 143–150.
Belaiba, R. S., Bonello, S., Zahringer, C.,
Schmidt, S., Hess, J., Kietzmann, T.,
and Gorlach,A. (2007). Hypoxia up-
regulates hypoxia-inducible factor-
1alpha transcription by involving
phosphatidylinositol 3-kinase and
nuclear factor kappaB in pulmonary
artery smooth muscle cells. Mol.
Biol. Cell 18, 4691–4697.
Biswas, S. K., and Lewis, C. E. (2010).
NF-kappaB as a central regulator of
macrophage function in tumors. J.
Leukoc. Biol. 88, 877–884.
Bosco, M. C., Puppo, M., Blengio, F.,
Fraone, T., Cappello, P., Giovarelli,
M., and Varesio, L. (2008). Mono-
cytes and dendritic cells in a hypoxic
environment: spotlights on chemo-
taxis and migration. Immunobiology
213, 733–749.
Bosco, M. C., Puppo, M., Pas-
torino, S., Mi, Z., Melillo, G.,
Massazza, S., Rapisarda, A., and
Varesio, L. (2004). Hypoxia selec-
tively inhibits monocyte chemoat-
tractant protein-1 production by
macrophages. J. Immunol. 172,
1681–1690.
Bosco, M. C., Puppo, M., Santangelo,
C., Anfosso, L., Pfeffer, U., Fardin,
P., Battaglia, F., and Varesio, L.
(2006). Hypoxia modiﬁes the tran-
scriptome of primary humanmono-
cytes:modulation of novel immune-
related genes and identiﬁcation of
CC-chemokine ligand 20 as a new
hypoxia-inducible gene. J. Immunol.
177, 1941–1955.
Bronte, V. (2009). Myeloid-derived
suppressor cells in inﬂamma-
tion: uncovering cell subsets with
enhanced immunosuppressive
functions. Eur. J. Immunol. 39,
2670–2672.
Burke, B., Tang, N., Corke, K. P.,
Tazzyman, D., Ameri, K., Wells, M.,
and Lewis, C. E. (2002). Expres-
sion of HIF-1alpha by human
macrophages: implications for the
use of macrophages in hypoxia-
regulated cancer gene therapy. J.
Pathol. 196, 204–212.
Bystrom, J., Evans, I., Newson, J., Sta-
bles, M., Toor, I., Van Rooijen, N.,
Crawford, M., Colville-Nash, P., Far-
row, S., and Gilroy, D. W. (2008).
Resolution-phase macrophages pos-
sess a unique inﬂammatory pheno-
type that is controlled by cAMP.
Blood 112, 4117–4127.
Carbia-Nagashima, A., Gerez, J., Perez-
Castro, C., Paez-Pereda, M., Silber-
stein, S., Stalla, G. K., Holsboer, F.,
and Arzt, E. (2007). RSUME, a small
RWD-containing protein, enhances
SUMO conjugation and stabilizes
HIF-1alpha during hypoxia. Cell
131, 309–323.
Chandel, N. S., Trzyna, W. C., Mcclin-
tock, D. S., and Schumacker, P.
T. (2000). Role of oxidants in
NF-kappa B activation and TNF-
alpha gene transcription induced by
hypoxia and endotoxin. J. Immunol.
165, 1013–1021.
Cheng, J., Kang, X., Zhang, S., and Yeh,
E. T. (2007). SUMO-speciﬁc pro-
tease 1 is essential for stabilization of
HIF1alpha during hypoxia. Cell 131,
584–595.
Cho, H., Ahn, D. R., Park, H., and Yang,
E. G. (2007). Modulation of p300
binding by posttranslational modiﬁ-
cations of the C-terminal activation
domain of hypoxia-inducible
factor-1alpha. FEBS Lett. 581,
1542–1548.
Cockman,M. E., Lancaster,D. E., Stolze,
I. P., Hewitson, K. S., Mcdonough,
M. A., Coleman, M. L., Coles, C.
H., Yu, X., Hay, R. T., Ley, S. C.,
Pugh, C. W., Oldham, N. J., Mas-
son, N., Schoﬁeld, C. J., and Rat-
cliffe, P. J. (2006). Posttranslational
hydroxylation of ankyrin repeats in
IkappaB proteins by the hypoxia-
inducible factor (HIF) asparaginyl
hydroxylase, factor inhibiting HIF
(FIH). Proc. Natl. Acad. Sci. U.S.A.
103, 14767–14772.
Coffelt, S. B., Hughes, R., and Lewis,
C. E. (2009). Tumor-associated
macrophages: effectors of angiogen-
esis and tumorprogression.Biochim.
Biophys. Acta 1796, 11–18.
Cramer, T., Yamanishi, Y., Clausen, B.
E., Forster, I., Pawlinski, R., Mack-
man, N., Haase, V. H., Jaenisch, R.,
Corr, M., Nizet, V., Firestein, G. S.,
Gerber, H. P., Ferrara, N., and John-
son, R. S. (2003). HIF-1alpha is
essential for myeloid cell-mediated
inﬂammation. Cell 112, 645–657.
Cros, J., Cagnard, N., Woollard, K.,
Patey, N., Zhang, S. Y., Senechal, B.,
Puel, A., Biswas, S. K., Moshous,
D., Picard, C., Jais, J. P., D’cruz,
D., Casanova, J. L., Trouillet, C.,
and Geissmann, F. (2010). Human
CD14dim monocytes patrol and
sense nucleic acids and viruses via
TLR7 andTLR8 receptors. Immunity
33, 375–386.
Crowther, M., Brown, N. J., Bishop,
E. T., and Lewis, C. E. (2001).
Microenvironmental inﬂuence on
macrophage regulation of angio-
genesis in wounds and malignant
tumors. J. Leukoc. Biol. 70, 478–490.
Cummins, E. P., Berra, E., Comerford,
K. M., Ginouves, A., Fitzgerald,
K. T., Seeballuck, F., Godson,
C., Nielsen, J. E., Moynagh, P.,
Pouyssegur, J., and Taylor, C.
T. (2006). Prolyl hydroxylase-
1 negatively regulates IkappaB
kinase-beta, giving insight into
hypoxia-induced NFkappaB activ-
ity. Proc. Natl. Acad. Sci. U.S.A. 103,
18154–18159.
Daniliuc, S., Bitterman, H., Rahat, M.
A., Kinarty, A., Rosenzweig, D., and
Lahat, N. (2003). Hypoxia inacti-
vates inducible nitric oxide synthase
in mouse macrophages by disrupt-
ing its interactionwith alpha-actinin
4. J. Immunol. 171, 3225–3232.
De Palma, M., Murdoch, C., Venneri,
M. A., Naldini, L., and Lewis, C. E.
(2007). Tie2-expressing monocytes:
regulation of tumor angiogenesis
and therapeutic implications.Trends
Immunol. 28, 519–524.
Demasi, M., Cleland, L. G., Cook-
Johnson, R. J., Caughey, G. E.,
and James, M. J. (2003). Effects of
hypoxia on monocyte inﬂammatory
mediator production: dissociation
between changes in cyclooxygenase-
2 expression and eicosanoid synthe-
sis. J. Biol. Chem. 278, 38607–38616.
Denko, N. C. (2008). Hypoxia, HIF1
and glucose metabolism in the
solid tumour. Nat. Rev. Cancer 8,
705–713.
Dlaska, M., and Weiss, G. (1999). Cen-
tral role of transcription factor NF-
IL6 for cytokine and iron-mediated
regulation of murine inducible
nitric oxide synthase expression. J.
Immunol. 162, 6171–6177.
Elbarghati, L., Murdoch, C., and Lewis,
C. E. (2008). Effects of hypoxia
on transcription factor expres-
sion in human monocytes and
macrophages. Immunobiology 213,
899–908.
Eltzschig, H. K. (2011). Targeting
hypoxia-induced inﬂammation.
Anesthesiology 114, 239–242.
Frontiers in Immunology | Inﬂammation September 2011 | Volume 2 | Article 45 | 12
Rahat et al. Hypoxic regulation of macrophage activation
Fang, H. Y., Hughes, R., Murdoch, C.,
Coffelt, S. B., Biswas, S. K., Harris,
A. L., Johnson, R. S., Imityaz, H. Z.,
Simon, M. C., Fredlund, E., Greten,
F. R., Rius, J., and Lewis,C. E. (2009).
Hypoxia-inducible factors 1 and 2
are important transcriptional effec-
tors in primarymacrophages experi-
encing hypoxia. Blood 114, 844–859.
Fitzpatrick, S. F., Tambuwala, M. M.,
Bruning, U., Schaible, B., Scholz, C.
C., Byrne, A., O’connor, A., Gal-
lagher, W. M., Lenihan, C. R., Gar-
vey, J. F., Howell, K., Fallon, P.
G., Cummins, E. P., and Taylor,
C. T. (2011). An intact canoni-
cal NF-kappaB pathway is required
for inﬂammatory gene expression
in response to hypoxia. J. Immunol.
186, 1091–1096.
Flugel, D., Gorlach, A., Michiels, C.,
and Kietzmann, T. (2007). Glycogen
synthase kinase 3 phosphorylates
hypoxia-inducible factor 1alpha and
mediates its destabilization in a
VHL-independent manner. Mol.
Cell. Biol. 27, 3253–3265.
Fong, C. H., Bebien, M., Didierlau-
rent, A., Nebauer, R., Hussell, T.,
Broide, D., Karin, M., and Lawrence,
T. (2008). An antiinﬂammatory role
for IKKbeta through the inhibition
of “classical”macrophage activation.
J. Exp. Med. 205, 1269–1276.
Frede, S., Stockmann, C., Freitag, P.,
and Fandrey, J. (2006). Bacter-
ial lipopolysaccharide induces HIF-
1 activation in human monocytes
via p44/42 MAPK and NF-kappaB.
Biochem. J. 396, 517–527.
Frede, S., Stockmann, C., Winning,
S., Freitag, P., and Fandrey, J.
(2009). Hypoxia-inducible factor
(HIF) 1alpha accumulation and HIF
target gene expression are impaired
after induction of endotoxin toler-
ance. J. Immunol. 182, 6470–6476.
Gabrilovich, D. I., and Nagaraj, S.
(2009). Myeloid-derived suppressor
cells as regulators of the immune sys-
tem. Nat. Rev. Immunol. 9, 162–174.
Galban, S., and Gorospe, M. (2009).
Factors interacting with HIF-1alpha
mRNA: novel therapeutic targets.
Curr. Pharm. Des. 15, 3853–3860.
Galban, S., Kuwano,Y., Pullmann, R. Jr.,
Martindale, J. L., Kim, H. H., Lal,
A.,Abdelmohsen,K.,Yang, X.,Dang,
Y., Liu, J. O., Lewis, S. M., Holcik,
M., and Gorospe, M. (2008). RNA-
binding proteins HuR and PTB pro-
mote the translation of hypoxia-
inducible factor 1alpha. Mol. Cell.
Biol. 28, 93–107.
Geissmann, F., Jung, S., and Littman, D.
R. (2003). Blood monocytes consist
of two principal subsets with distinct
migratory properties. Immunity 19,
71–82.
Gordon, S., and Martinez, F. O.
(2010). Alternative activation of
macrophages: mechanism and func-
tions. Immunity 32, 593–604.
Gorgoni, B., Maritano, D., Marthyn,
P., Righi, M., and Poli, V. (2002).
C/EBP beta gene inactivation causes
both impaired and enhanced gene
expression and inverse regulation
of IL-12 p40 and p35 mRNAs
in macrophages. J. Immunol. 168,
4055–4062.
Grifﬁths, L., Binley, K., Iqball, S., Kan,
O., Maxwell, P., Ratcliffe, P., Lewis,
C., Harris, A., Kingsman, S., and
Naylor, S. (2000). The macrophage
– a novel system to deliver gene ther-
apy to pathological hypoxia. Gene
Ther. 7, 255–262.
Grivennikov, S. I., and Karin,M. (2010).
Dangerous liaisons: STAT3 and NF-
kappaB collaboration and crosstalk
in cancer. Cytokine Growth Factor
Rev. 21, 11–19.
Grocott, M. P., Martin, D. S., Levett, D.
Z., Mcmorrow, R., Windsor, J., and
Montgomery, H. E. (2009). Arterial
blood gases and oxygen content in
climbers on Mount Everest. N. Engl.
J. Med. 360, 140–149.
Guida, E., and Stewart, A. (1998). Inﬂu-
ence of hypoxia and glucose depri-
vation on tumour necrosis factor-
alpha and granulocyte-macrophage
colony-stimulating factor expres-
sion in human cultured monocytes.
Cell. Physiol. Biochem. 8, 75–88.
Hagemann, T., Biswas, S. K., Lawrence,
T., Sica, A., and Lewis, C. E. (2009).
Regulation of macrophage function
in tumors: the multifaceted role of
NF-kappaB. Blood 113, 3139–3146.
Hartmann, G., Tschop, M., Fischer, R.,
Bidlingmaier, C., Riepl, R., Tschop,
K., Hautmann, H., Endres, S., and
Toepfer, M. (2000). High altitude
increases circulating interleukin-6,
interleukin-1 receptor antagonist
and C-reactive protein. Cytokine 12,
246–252.
Heikkila, M., Pasanen, A., Kivirikko, K.
I., and Myllyharju, J. (2011). Roles
of the humanhypoxia-inducible fac-
tor (HIF)-3alpha variants in the
hypoxia response. Cell. Mol. Life Sci.
PMID: 21479871. [Epub ahead of
print].
Hudson, C. C., Liu, M., Chiang, G.
G., Otterness, D. M., Loomis, D.
C., Kaper, F., Giaccia, A. J., and
Abraham, R. T. (2002). Regulation
of hypoxia-inducible factor 1alpha
expression and function by the
mammalian target of rapamycin.
Mol. Cell. Biol. 22, 7004–7014.
Ivanov, S. V., Salnikow, K., Ivanova, A.
V., Bai, L., and Lerman, M. I. (2007).
Hypoxic repression of STAT1 and its
downstreamgenes by a pVHL/HIF-1
target DEC1/STRA13. Oncogene 26,
802–812.
Jafarifar, F., Yao, P., Eswarappa, S. M.,
and Fox, P. L. (2011). Repression of
VEGFA by CA-rich element-binding
microRNAs is modulated by hnRNP
L. EMBO J. 30, 1324–1334.
Janardhan, H. P. (2008). The HIF-1
alpha-C/EBP alpha axis. Sci. Signal.
1, jc2.
Kang, S. H., Yu, M. O., Park, K. J., Chi,
S. G., Park, D. H., and Chung, Y.
G. (2010).Activated STAT3 regulates
hypoxia-induced angiogenesis and
cell migration in human glioblas-
toma. Neurosurgery 67, 1386–1395;
discussion 1395.
Khabar, K. S. (2010). Post-
transcriptional control during
chronic inﬂammation and cancer:
a focus on AU-rich elements. Cell.
Mol. Life Sci. 67, 2937–2955.
Kim, D., Kim, Y. J., Koh, H. S., Jang,
T. Y., Park, H. E., and Kim, J.
Y. (2010). Reactive oxygen species
enhance TLR10 expression in the
human monocytic cell line THP-1.
Int. J. Mol. Sci. 11, 3769–3782.
Laderoute, K. R. (2005). The interac-
tion between HIF-1 and AP-1 tran-
scription factors in response to low
oxygen. Semin. Cell Dev. Biol. 16,
502–513.
Laderoute, K. R., Alarcon, R. M., Brody,
M. D., Calaoagan, J. M., Chen, E. Y.,
Knapp, A. M., Yun, Z., Denko, N.
C., and Giaccia, A. J. (2000). Oppos-
ing effects of hypoxia on expres-
sion of the angiogenic inhibitor
thrombospondin 1 and the angio-
genic inducer vascular endothelial
growth factor. Clin. Cancer Res. 6,
2941–2950.
Lahat, N., Bitterman, H., Engelmayer-
Goren, M., Rosenzweig, D., Weiss-
Cerem, L., and Rahat, M. A.
(2011). Reduced TIMP-2 in hypoxia
enhances angiogenesis. Am. J. Phys-
iol. Cell Physiol. 300, C557–C566.
Lahat, N., Rahat, M. A., Ballan, M.,
Weiss-Cerem, L., Engelmayer,
M., and Bitterman, H. (2003).
Hypoxia reduces CD80 expres-
sion on monocytes but enhances
their LPS-stimulated TNF-alpha
secretion. J. Leukoc. Biol. 74,
197–205.
Lahat, N., Rahat, M. A., Kinarty,
A., Weiss-Cerem, L., Pinchevski,
S., and Bitterman, H. (2008).
Hypoxia enhances lysosomal TNF-
alpha degradation in mouse peri-
toneal macrophages. Am. J. Physiol.,
Cell Physiol. 295, C2–C12.
Lawrence, T., and Fong, C. (2010).
The resolution of inﬂammation:
anti-inﬂammatory roles for NF-
kappaB. Int. J. Biochem. Cell Biol. 42,
519–523.
Lee, K. J., Lee, K. Y., and Lee, Y.
M. (2010). Downregulation of a
tumor suppressor RECK by hypoxia
through recruitment of HDAC1 and
HIF-1alpha to reverse HRE site in
the promoter.Biochim. Biophys. Acta
1803, 608–616.
Lee, M. Y., Joung, Y. H., Lim, E. J., Park,
J. H., Ye, S. K., Park, T., Zhang, Z.,
Park,D. K., Lee, K. J., andYang,Y. M.
(2006). Phosphorylation and activa-
tion of STAT proteins by hypoxia
in breast cancer cells. Breast 15,
187–195.
Leeper-Woodford, S. K., and Detmer,
K. (1999). Acute hypoxia increases
alveolar macrophage tumor necro-
sis factor activity and alters NF-
kappaB expression. Am. J. Physiol.
276, L909–L916.
Lewis, C. E., and Pollard, J. W. (2006).
Distinct role of macrophages in dif-
ferent tumor microenvironments.
Cancer Res. 66, 605–612.
Lewis, J. S., Lee, J. A., Underwood, J. C.,
Harris,A. L., and Lewis,C. E. (1999).
Macrophage responses to hypoxia:
relevance to disease mechanisms. J.
Leukoc. Biol. 66, 889–900.
Li, F., Sonveaux, P., Rabbani, Z. N., Liu,
S.,Yan, B., Huang,Q.,Vujaskovic, Z.,
Dewhirst,M.W., and Li,C.Y. (2007).
Regulation of HIF-1alpha stability
through S-nitrosylation. Mol. Cell
26, 63–74.
Li, P., Lu, J., Kaur, C., Sivakumar,V., Tan,
K. L., and Ling, E. A. (2009). Expres-
sion of cyclooxygenase-1/-2, micro-
somal prostaglandin-E synthase-1
and E-prostanoid receptor 2 and
regulation of inﬂammatory medi-
ators by PGE(2) in the amoeboid
microglia in hypoxic postnatal rats
and murine BV-2 cells. Neuroscience
164, 948–962.
Li, S. H., Chun, Y. S., Lim, J. H., Huang,
L. E., and Park, J. W. (2011). von
Hippel-Lindau protein adjusts oxy-
gen sensing of the FIH asparaginyl
hydroxylase. Int. J. Biochem. Cell
Biol. 43, 795–804.
Liao, H., Hyman, M. C., Lawrence,
D. A., and Pinsky, D. J. (2007).
Molecular regulation of the
PAI-1 gene by hypoxia: contri-
butions of Egr-1, HIF-1alpha,
and C/EBPalpha. FASEB J. 21,
935–949.
Luo, W., Hu, H., Chang, R., Zhong,
J., Knabel, M., O’Meally, R., Cole,
R. N., Pandey, A., and Semenza, G.
L. (2011). Pyruvate kinase M2 is
a PHD3-stimulated coactivator for
hypoxia-inducible factor 1. Cell 145,
732–744.
Mancino, A., and Lawrence, T. (2010).
Nuclear factor-kappaB and tumor-
associated macrophages. Clin. Can-
cer Res. 16, 784–789.
www.frontiersin.org September 2011 | Volume 2 | Article 45 | 13
Rahat et al. Hypoxic regulation of macrophage activation
Martinez, F. O., Helming, L., and Gor-
don, S. (2009). Alternative activa-
tion of macrophages: an immuno-
logic functional perspective. Annu.
Rev. Immunol. 27, 451–483.
Martinez, F. O., Sica, A., Mantovani, A.,
and Locati, M. (2008). Macrophage
activation and polarization. Front.
Biosci. 13, 453–461.
Matzinger, P. (2002). The dangermodel:
a renewed sense of self. Science 296,
301–305.
Melillo, G., Taylor, L. S., Brooks, A.,
Cox, G. W., and Varesio, L. (1996).
Regulation of inducible nitric oxide
synthase expression in IFN-gamma-
treated murine macrophages cul-
tured under hypoxic conditions. J.
Immunol. 157, 2638–2644.
Meng, X., Ao, L., Shames, B. D., and
Harken, A. H. (2001). Inhibition
of cyclic-3′,5′-nucleotide phospho-
diesterase abrogates the synergismof
hypoxia with lipopolysaccharide in
the induction of macrophage TNF-
alpha production. J. Surg. Res. 101,
210–215.
Minko, T., Wang, Y., and Pozharov,
V. (2005). Remediation of cellular
hypoxic damage by pharmacolog-
ical agents. Curr. Pharm. Des. 11,
3185–3199.
Mosser, D. M. (2003). The many faces
of macrophage activation. J. Leukoc.
Biol. 73, 209–212.
Mosser, D. M., and Edwards, J. P.
(2008). Exploring the full spectrum
of macrophage activation. Nat. Rev.
Immunol. 8, 958–969.
Murdoch,C.,Giannoudis,A., andLewis,
C. E. (2004). Mechanisms regulat-
ing the recruitment of macrophages
into hypoxic areas of tumors and
other ischemic tissues. Blood 104,
2224–2234.
Murdoch, C., Muthana, M., Coffelt, S.
B., and Lewis, C. E. (2008). The role
of myeloid cells in the promotion
of tumour angiogenesis. Nat. Rev.
Cancer 8, 618–631.
Murdoch, C., Muthana, M., and Lewis,
C. E. (2005). Hypoxia regulates
macrophage functions in inﬂamma-
tion. J. Immunol. 175, 6257–6263.
Mylonis, I., Chachami, G., Samio-
taki, M., Panayotou, G., Paraskeva,
E., Kalousi, A., Georgatsou, E.,
Bonanou, S., and Simos, G. (2006).
Identiﬁcation of MAPK phospho-
rylation sites and their role in
the localization and activity of
hypoxia-inducible factor-1alpha. J.
Biol. Chem. 281, 33095–33106.
Nahid, M. A., Pauley, K. M., Satoh,
M., and Chan, E. K. (2009). miR-
146a is critical for endotoxin-
induced tolerance: implication in
innate immunity. J. Biol. Chem. 284,
34590–34599.
Nahid, M. A., Satoh, M., and Chan,
E. K. (2011). Mechanistic role
of microRNA-146a in endotoxin-
induced differential cross-regulation
of TLR signaling. J. Immunol. 186,
1723–1734.
Nahrendorf, M., Pittet, M. J., and
Swirski, F. K. (2010). Monocytes:
protagonists of infarct inﬂammation
and repair after myocardial infarc-
tion. Circulation 121, 2437–2445.
Niu, G., Briggs, J., Deng, J., Ma, Y.,
Lee, H., Kortylewski, M., Kujawski,
M., Kay, H., Cress, W. D., Jove, R.,
and Yu, H. (2008). Signal trans-
ducer and activator of transcrip-
tion 3 is required for hypoxia-
inducible factor-1alphaRNAexpres-
sion in both tumor cells and tumor-
associatedmyeloid cells.Mol. Cancer
Res. 6, 1099–1105.
Nizet, V., and Johnson, R. S. (2009).
Interdependence of hypoxic and
innate immune responses. Nat. Rev.
Immunol. 9, 609–617.
Noman, M. Z., Buart, S., Van Pelt,
J., Richon, C., Hasmim, M., Leleu,
N., Suchorska, W. M., Jalil, A.,
Lecluse, Y., El Hage, F., Giuliani, M.,
Pichon,C.,Azzarone, B.,Mazure,N.,
Romero, P., Mami-Chouaib, F., and
Chouaib, S. (2009). The coopera-
tive induction of hypoxia-inducible
factor-1 alpha and STAT3 during
hypoxia induced an impairment
of tumor susceptibility to CTL-
mediated cell lysis. J. Immunol. 182,
3510–3521.
O’Connell, R. M., Taganov, K. D.,
Boldin, M. P., Cheng, G., and Bal-
timore, D. (2007). MicroRNA-155
is induced during the macrophage
inﬂammatory response. Proc. Natl.
Acad. Sci. U.S.A. 104, 1604–1609.
Oda, T., Hirota, K., Nishi, K., Tak-
abuchi, S., Oda, S., Yamada, H.,
Arai, T., Fukuda, K., Kita, T.,
Adachi, T., Semenza, G. L., and
Nohara, R. (2006). Activation of
hypoxia-inducible factor 1 during
macrophage differentiation. Am. J.
Physiol. Cell Physiol. 291, C104–
C113.
Ostrand-Rosenberg, S., and Sinha, P.
(2009). Myeloid-derived suppressor
cells: linking inﬂammation and can-
cer. J. Immunol. 182, 4499–4506.
Papandreou, I., Powell, A., Lim, A.
L., and Denko, N. (2005). Cellu-
lar reaction to hypoxia: sensing and
responding to an adverse environ-
ment. Mutat. Res. 569, 87–100.
Patel, S. A., and Simon, M. C. (2008).
Biology of hypoxia-inducible factor-
2alpha in development and disease.
Cell Death Differ. 15, 628–634.
Pautz, A., Art, J., Hahn, S., Nowag,
S., Voss, C., and Kleinert, H.
(2010). Regulation of the expression
of inducible nitric oxide synthase.
Nitric Oxide 23, 75–93.
Peyssonnaux, C., Cejudo-Martin, P.,
Doedens, A., Zinkernagel, A. S.,
Johnson, R. S., and Nizet, V. (2007).
Cutting edge: essential role of
hypoxia inducible factor-1alpha in
development of lipopolysaccharide-
induced sepsis. J. Immunol. 178,
7516–7519.
Pocock, R. (2011). Invited review:
decoding the microRNA response to
hypoxia.PﬂugersArch. 461,307–315.
Qian, B. Z., and Pollard, J. W. (2010).
Macrophage diversity enhances
tumor progression and metastasis.
Cell 141, 39–51.
Qu, X., Yang, M. X., Kong, B. H., Qi, L.,
Lam, Q. L., Yan, S., Li, P., Zhang, M.,
and Lu, L. (2005). Hypoxia inhibits
the migratory capacity of human
monocyte-derived dendritic cells.
Immunol. Cell Biol. 83, 668–673.
Rahat, M. A., Marom, B., Bitterman,
H., Weiss-Cerem, L., Kinarty, A.,
and Lahat, N. (2006). Hypoxia
reduces the output of matrix
metalloproteinase-9 (MMP-9) in
monocytes by inhibiting its secre-
tion and elevating membranal asso-
ciation. J. Leukoc. Biol. 79, 706–718.
Ramanathan, M., Luo, W., Csoka,
B., Hasko, G., Lukashev, D.,
Sitkovsky, M. V., and Leibovich, S.
J. (2009). Differential regulation
of HIF-1alpha isoforms in murine
macrophages by TLR4 and adeno-
sine A(2A) receptor agonists. J.
Leukoc. Biol. 86, 681–689.
Ray, P. S., Jia, J., Yao, P., Majumder, M.,
Hatzoglou,M., and Fox, P. L. (2009).
A stress-responsive RNA switch reg-
ulates VEGFA expression. Nature
457, 915–919.
Rius, J., Guma, M., Schachtrup, C.,
Akassoglou, K., Zinkernagel, A. S.,
Nizet, V., Johnson, R. S., Haddad,
G. G., and Karin, M. (2008). NF-
kappaB links innate immunity to the
hypoxic response through transcrip-
tional regulation of HIF-1alpha.
Nature 453, 807–811.
Rosenberger, P., Schwab, J. M., Mirakaj,
V., Masekowsky, E., Mager, A.,
Morote-Garcia, J. C., Unertl, K., and
Eltzschig, H. K. (2009). Hypoxia-
inducible factor-dependent induc-
tion of netrin-1 dampens inﬂam-
mation caused by hypoxia. Nat.
Immunol. 10, 195–202.
Saccani, A., Schioppa, T., Porta, C.,
Biswas, S. K., Nebuloni, M., Vago,
L., Bottazzi, B., Colombo, M.
P., Mantovani, A., and Sica, A.
(2006). p50 nuclear factor-kappaB
overexpression in tumor-associated
macrophages inhibitsM1 inﬂamma-
tory responses and antitumor resis-
tance. Cancer Res. 66, 11432–11440.
Sakamoto, T., and Seiki, M. (2010). A
membrane protease regulates energy
production in macrophages by acti-
vating hypoxia-inducible factor-1
via a non-proteolytic mechanism. J.
Biol. Chem. 285, 29951–29964.
Scannell, G., Waxman, K., Kaml, G. J.,
Ioli, G., Gatanaga, T., Yamamoto, R.,
and Granger, G. A. (1993). Hypoxia
induces a human macrophage cell
line to release tumor necrosis
factor-alpha and its soluble recep-
tors in vitro. J. Surg. Res. 54,
281–285.
Schif-Zuck, S., Gross, N., Assi, S., Ros-
toker, R., Serhan, C. N., and Ariel,
A. (2011). Saturated-efferocytosis
generates pro-resolving CD11b
low macrophages: modulation by
resolvins and glucocorticoids. Eur.
J. Immunol. 41, 366–379.
Schioppa, T., Uranchimeg, B., Saccani,
A., Biswas, S. K., Doni, A., Rapis-
arda, A., Bernasconi, S., Saccani, S.,
Nebuloni, M., Vago, L., Mantovani,
A., Melillo, G., and Sica, A. (2003).
Regulation of the chemokine recep-
tor CXCR4 by hypoxia. J. Exp. Med.
198, 1391–1402.
Schroder, K., Sweet, M. J., and Hume,
D. A. (2006). Signal integration
between IFNgamma and TLR sig-
nalling pathways in macrophages.
Immunobiology 211, 511–524.
Shin, I. J., Park, B. K., Ahn, Y. T.,
Kim, Y., and An, W. G. (2010).
Actin disruption inhibits hypoxia
inducible factor-1alpha expression
via inactivity of Mdm2-mediated
p70S6K. Mol. Med. Report 3,
815–819.
Shirato, K., Kizaki, T., Sakurai, T.,
Ogasawara, J. E., Ishibashi, Y.,
Iijima, T., Okada, C., Noguchi,
I., Imaizumi, K., Taniguchi, N.,
and Ohno, H. (2009). Hypoxia-
inducible factor-1alpha suppresses
the expression of macrophage scav-
enger receptor 1. Pﬂugers Arch. 459,
93–103.
Sica, A., Allavena, P., and Mantovani,
A. (2008). Cancer related inﬂamma-
tion: the macrophage connection.
Cancer Lett. 267, 204–215.
Sica, A., Saccani, A., Bottazzi, B.,
Polentarutti, N., Vecchi, A., Van
Damme, J., and Mantovani, A.
(2000). Autocrine production of IL-
10 mediates defective IL-12 pro-
duction and NF-kappa B activation
in tumor-associated macrophages. J.
Immunol. 164, 762–767.
Skrzeczynska-Moncznik, J., Bzowska,
M., Loseke, S., Grage-Griebenow,
E., Zembala, M., and Pryjma, J.
(2008). Peripheral blood CD14high
CD16+ monocytes are main pro-
ducers of IL-10. Scand. J. Immunol.
67, 152–159.
Frontiers in Immunology | Inﬂammation September 2011 | Volume 2 | Article 45 | 14
Rahat et al. Hypoxic regulation of macrophage activation
Sow, F. B., Alvarez, G. R., Gross, R. P.,
Satoskar, A. R., Schlesinger, L. S.,
Zwilling, B. S., and Lafuse, W. P.
(2009). Role of STAT1, NF-kappaB,
and C/EBPbeta in the macrophage
transcriptional regulation of hep-
cidin by mycobacterial infection and
IFN-gamma. J. Leukoc. Biol. 86,
1247–1258.
Sperandio, S., Fortin, J., Sasik, R.,
Robitaille, L., Corbeil, J., and De
Belle, I. (2009). The transcription
factor Egr1 regulates the HIF-1alpha
gene during hypoxia. Mol. Carcinog.
48, 38–44.
Staples, K. J., Sotoodehnejadnemata-
lahi, F., Pearson, H., Frankenberger,
M., Francescut, L., Ziegler-
Heitbrock, L., and Burke, B. (2010).
Monocyte-derived macrophages
matured under prolonged hypoxia
transcriptionally up-regulate HIF-
1alpha mRNA. Immunobiology 216,
832–839.
Stout, R. D., and Suttles, J. (2004). Func-
tional plasticity of macrophages:
reversible adaptation to changing
microenvironments. J. Leukoc. Biol.
76, 509–513.
Stout, R. D., Watkins, S. K., and Suttles,
J. (2009). Functional plasticity
of macrophages: in situ repro-
gramming of tumor-associated
macrophages. J. Leukoc. Biol. 86,
1105–1109.
Sumbayev, V. V., Budde, A., Zhou, J.,
and Brune, B. (2003). HIF-1 alpha
protein as a target for S-nitrosation.
FEBS Lett. 535, 106–112.
Taganov, K. D., Boldin, M. P., Chang,
K. J., and Baltimore, D. (2006).
NF-kappaB-dependent induction
of microRNA miR-146, an inhibitor
targeted to signaling proteins
of innate immune responses.
Proc. Natl. Acad. Sci. U.S.A. 103,
12481–12486.
Takeda, K., Ichiki, T., Narabayashi,
E., Inanaga, K., Miyazaki, R.,
Hashimoto, T., Matsuura, H., Ikeda,
J., Miyata, T., and Sunagawa, K.
(2009). Inhibition of prolyl hydroxy-
lase domain-containing protein sup-
pressed lipopolysaccharide-induced
TNF-alpha expression. Arterioscler.
Thromb. Vasc. Biol. 29, 2132–2137.
Takeda, N., O’dea, E. L., Doedens, A.,
Kim, J. W., Weidemann, A., Stock-
mann, C., Asagiri, M., Simon, M.
C., Hoffmann, A., and Johnson,
R. S. (2010). Differential activation
and antagonistic function of HIF-
{alpha} isoforms in macrophages are
essential for NO homeostasis. Genes
Dev. 24, 491–501.
Thulasingam, S., Massilamany, C., Gan-
gaplara, A., Dai, H., Yarbaeva, S.,
Subramaniam, S., Riethoven, J. J.,
Eudy, J., Lou, M., and Reddy,
J. (2011). miR-27b∗, an oxidative
stress-responsive microRNA modu-
lates nuclear factor-kB pathway in
RAW 264.7 cells. Mol. Cell. Biochem.
352, 181–188.
Vallabhapurapu, S., and Karin, M.
(2009). Regulation and function of
NF-kappaB transcription factors in
the immune system. Annu. Rev.
Immunol. 27, 693–733.
van de Veerdonk, F. L., and Netea,
M. G. (2010). Diversity: a hallmark
of monocyte society. Immunity 33,
289–291.
Vasudevan, S., Tong, Y., and Steitz, J.
A. (2007). Switching from repres-
sion to activation: microRNAs can
up-regulate translation. Science 318,
1931–1934.
Venneri, M. A., De Palma, M., Pon-
zoni, M., Pucci, F., Scielzo, C.,
Zonari, E., Mazzieri, R., Doglioni,
C., and Naldini, L. (2007). Iden-
tiﬁcation of proangiogenic TIE2-
expressing monocytes (TEMs) in
human peripheral blood and cancer.
Blood 109, 5276–5285.
Walmsley, S. R., Chilvers, E. R., and
Whyte, M. K. (2009). Hypoxia.
Hypoxia, hypoxia inducible factor
and myeloid cell function. Arthritis
Res. Ther. 11, 219.
Walmsley, S. R., Mcgovern, N. N.,
Whyte, M. K., and Chilvers, E.
R. (2008). The HIF/VHL path-
way: from oxygen sensing to innate
immunity. Am. J. Respir. Cell Mol.
Biol. 38, 251–255.
Weigert, A., and Brune, B. (2008).
Nitric oxide, apoptosis and
macrophage polarization during
tumor progression. Nitric Oxide 19,
95–102.
Werno, C., Menrad, H., Weigert, A.,
Dehne, N., Goerdt, S., Schledzewski,
K., Kzhyshkowska, J., and Brune, B.
(2010a). Knockout of HIF-1alpha
in tumor-associated macrophages
enhances M2 polarization and
attenuates their pro-angiogenic
responses. Carcinogenesis 31,
1863–1872.
Werno, C., Schmid, T., Schnitzer, S.
E., Peters, K., Milke, L., and Brune,
B. (2010b). A combination of
hypoxia and lipopolysaccharide acti-
vates tristetraprolin to destabilize
proinﬂammatory mRNAs such as
tumor necrosis factor-alpha. Am. J.
Pathol. 177, 1104–1112.
Westra, J., Brouwer, E., Van Roosmalen,
I. A., Doornbos-Van Der Meer,
B., Van Leeuwen, M. A., Posthu-
mus, M. D., and Kallenberg, C. G.
(2010). Expression and regulation of
HIF-1alpha in macrophages under
inﬂammatory conditions; signiﬁ-
cant reduction of VEGF by CaMKII
inhibitor. BMC Musculoskelet. Dis-
ord. 11, 61. doi: 10.1186/1471-2474-
11-61
Xu, Y., Toure, F., Qu, W., Lin, L.,
Song, F., Shen, X., Rosario, R., Gar-
cia, J., Schmidt, A. M., and Yan, S.
F. (2010). Advanced glycation end
product (AGE)-receptor for AGE
(RAGE) signaling and up-regulation
of Egr-1 in hypoxic macrophages. J.
Biol. Chem. 285, 23233–23240.
Yang, L., Jiang, Y., Wu, S. F., Zhou,
M. Y., Wu, Y. L., and Chen, G. Q.
(2008). CCAAT/enhancer-binding
protein alpha antagonizes transcrip-
tional activity of hypoxia-inducible
factor 1 alpha with direct protein-
protein interaction. Carcinogenesis
29, 291–298.
Yee Koh, M., Spivak-Kroizman, T. R.,
and Powis, G. (2008). HIF-1 regu-
lation: not so easy come, easy go.
Trends Biochem. Sci. 33, 526–534.
Yoon, S. O., Shin, S., and Mercurio, A.
M. (2005). Hypoxia stimulates carci-
noma invasion by stabilizing micro-
tubules and promoting the Rab11
trafﬁcking of the alpha6beta4 inte-
grin. Cancer Res. 65, 2761–2769.
Yun, J. K., Mccormick, T. S., Villabona,
C., Judware, R. R., Espinosa, M. B.,
and Lapetina, E. G. (1997). Inﬂam-
matorymediators are perpetuated in
macrophages resistant to apoptosis
inducedbyhypoxia.Proc.Natl.Acad.
Sci. U.S.A. 94, 13903–13908.
Zampetaki, A., Mitsialis, S. A.,
Pfeilschifter, J., and Kourem-
banas, S. (2004). Hypoxia induces
macrophage inﬂammatory protein-
2 (MIP-2) gene expression inmurine
macrophages via NF-kappaB: the
prominent role of p42/p44 and
PI3 kinase pathways. FASEB J. 18,
1090–1092.
Zhao, P., Li, X. G., Yang, M., Shao, Q.,
Wang, D., Liu, S., Song, H., Song,
B., Zhang, Y., and Qu, X. (2008).
Hypoxia suppresses the production
of MMP-9 by human monocyte-
derived dendritic cells and requires
activation of adenosine receptorA2b
via cAMP/PKA signaling pathway.
Mol. Immunol. 45, 2187–2195.
Ziegler-Heitbrock, L. (2007). The
CD14+ CD16+ blood mono-
cytes: their role in infection and
inﬂammation. J. Leukoc. Biol. 81,
584–592.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 30 June 2011; paper pend-
ing published: 22 July 2011; accepted:
29 August 2011; published online: 16
September 2011.
Citation: Rahat MA, Bitterman H and
Lahat N (2011) Molecular mecha-
nisms regulating macrophage response
to hypoxia. Front. Immun. 2:45. doi:
10.3389/ﬁmmu.2011.00045
This article was submitted to Frontiers in
Inﬂammation, a specialty of Frontiers in
Immunology.
Copyright © 2011 Rahat , Bitterman and
Lahat . This is an open-access article sub-
ject to a non-exclusive license between the
authors and Frontiers Media SA, which
permits use, distribution and reproduc-
tion in other forums, provided the original
authors and source are credited and other
Frontiers conditions are complied with.
www.frontiersin.org September 2011 | Volume 2 | Article 45 | 15
